[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 434
1. Hori Y, Uechi M, Kanakubo K, Sano T, Oyamada T: Canine ovarian serous papillary adenocarcinoma with neoplastic hypercalcemia. J Vet Med Sci; 2006 Sep;68(9):979-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine ovarian serous papillary adenocarcinoma with neoplastic hypercalcemia.
  • The right ovarian mass was diagnosed as a serous papillary adenocarcinoma.
  • Therefore, concentrations of PTH-rP and calcium might be associated with serous papillary adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019069.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Eilon T, Barash I: Different gene-expression profiles for the poorly differentiated carcinoma and the highly differentiated papillary adenocarcinoma in mammary glands support distinct metabolic pathways. BMC Cancer; 2008;8:270
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different gene-expression profiles for the poorly differentiated carcinoma and the highly differentiated papillary adenocarcinoma in mammary glands support distinct metabolic pathways.
  • Poorly differentiated carcinoma and highly differentiated papillary adenocarcinoma tumors evolve.
  • These tumors displayed either the carcinoma or the papillary adenocarcinoma phenotypes. cRNAs, prepared from each tumor were hybridized to an Affymetrix GeneChip(R) Mouse Genome 430A 2.0 array.
  • Higher expression of genes encoding the degradation complex of the canonical pathway and limited TCF expression in the papillary adenocarcinoma result in membranal accumulation of beta-catenin, in contrast to its nuclear translocation in the carcinoma.
  • Genes involved in cell-cycle arrest at G1 and response to DNA damage were more highly expressed in the papillary adenocarcinomas, as opposed to favored G2/M regulation in the carcinoma tumors.
  • CONCLUSION: At least six metabolic pathways support the morphological and functional differences between carcinomas and papillary adenocarcinomas.
  • Cell-cell contact, polarity, earlier cell-cycle arrest and DNA damage control are better displayed in the papillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Carcinoma / genetics. Gene Expression Profiling. Mammary Neoplasms, Animal / genetics. Metabolic Networks and Pathways / genetics. Oligonucleotide Array Sequence Analysis

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):167-80 [7831528.001]
  • [Cites] Pathobiology. 2006;73(5):213-23 [17314492.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1873-80 [9717814.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7748-55 [15520179.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):171-8 [15308542.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68 [15688067.001]
  • [Cites] Clin Breast Cancer. 2005 Apr;6(1):61-76 [15899074.001]
  • [Cites] J Cell Sci. 2005 Sep 1;118(Pt 17):3829-38 [16129881.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):914-26 [16167329.001]
  • [Cites] Immunol Lett. 2007 Mar 15;109(1):1-12 [17287030.001]
  • [Cites] Mol Cancer Res. 2002 Nov;1(1):32-47 [12496367.001]
  • [Cites] J Biol Chem. 2002 Oct 4;277(40):37479-86 [12138115.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):1892-902 [17640063.001]
  • [Cites] Mol Biol Cell. 2003 Mar;14(3):1027-42 [12631721.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] J Cell Sci. 2000 Mar;113 ( Pt 6):911-9 [10683140.001]
  • [Cites] Mod Pathol. 2000 Jul;13(7):730-5 [10912931.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5606-13 [11114741.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):10-8 [11232942.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):355-64 [11547903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2246-51 [11854519.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2134-42 [12001109.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6598-608 [14528285.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Oct;4(10):786-97 [14570055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]
  • [Cites] Breast Cancer Res Treat. 2004 May;85(1):13-22 [15039594.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2825-37 [15077146.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3572-9 [15150114.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):997-1007 [15279786.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):959-65 [15305200.001]
  • [Cites] IEEE Trans Nanobioscience. 2003 Sep;2(3):163-70 [15376951.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):607-19 [15382041.001]
  • [Cites] Cell Cycle. 2005 Dec;4(12):1808-16 [16294019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18556-61 [16339305.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):819-26 [16467094.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):99-106 [16491069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3799-804 [16501043.001]
  • [Cites] Thyroid. 2006 Feb;16(2):161-75 [16676402.001]
  • [Cites] Nat Immunol. 2006 Jun;7(6):634-43 [16699526.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(1):85-90 [16541313.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):41-52 [16947085.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):499-506 [16859905.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):541-8 [16905303.001]
  • [Cites] Trends Mol Med. 2006 Nov;12(11):537-44 [17011236.001]
  • [Cites] J Mol Histol. 2006 Sep;37(5-7):253-60 [16841236.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):90-101 [17200343.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R56 [17014703.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2334-43 [9528803.001]
  • (PMID = 18811984.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2564980
  •  go-up   go-down


3. Yamashita S, Inaba Y, Soma F, Katayama Y: Pure prostatic papillary adenocarcinoma with ductal features. Hinyokika Kiyo; 2005 Mar;51(3):207-9; discussion 210
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure prostatic papillary adenocarcinoma with ductal features.
  • Papillary adenocarcinoma resembling ductal carcinoma and arising in the peripheral zone is extremely rare.
  • We report a case of prostatic papillary adenocarcinoma with ductal features.
  • Prostatic needle biopsy findings supported pathological diagnosis of prostatitis.
  • Transrectal needle biopsy of the mass was performed, and papillary adenocarcinoma was suspected by histological examination.
  • Histological and immunohistochemical examination of the prostatectomy specimen revealed pure prostatic papillary adenocarcinoma with ductal features.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Carcinoma, Ductal / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852679.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Reymann S, Borlak J: Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network. BMC Syst Biol; 2008;2:46
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription profiling of lung adenocarcinomas of c-myc-transgenic mice: identification of the c-myc regulatory gene network.
  • Targeted overexpression of this gene in mice results in distinct types of lung adenocarcinomas.
  • By using microarray technology, alterations in the expression of genes were captured based on a female transgenic mouse model in which, indeed, c-Myc overexpression in alveolar epithelium results in the development of bronchiolo-alveolar carcinoma (BAC) and papillary adenocarcinoma (PLAC).
  • [MeSH-major] Adenocarcinoma / metabolism. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic / genetics. Lung Neoplasms / metabolism. Models, Biological. Proto-Oncogene Proteins c-myc / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5313-8 [12702757.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3576-9 [12824369.001]
  • [Cites] Science. 1991 Mar 8;251(4998):1211-7 [2006410.001]
  • [Cites] Oncogene. 1991 Nov;6(11):1941-8 [1658705.001]
  • [Cites] Cell Growth Differ. 1992 Mar;3(3):183-90 [1633109.001]
  • [Cites] EMBO J. 1993 Aug;12(8):3237-47 [8344261.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8 [8356088.001]
  • [Cites] Nucleic Acids Res. 1993 Aug 11;21(16):3767-75 [8367294.001]
  • [Cites] EMBO J. 1993 Dec 15;12(13):5083-7 [8262051.001]
  • [Cites] Genes Dev. 1994 Jul 1;8(13):1526-37 [7958837.001]
  • [Cites] Science. 1995 Jan 20;267(5196):389-93 [7824938.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1536-44 [7862146.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1508-19 [7729426.001]
  • [Cites] Biochemistry. 1995 Dec 19;34(50):16503-8 [8845379.001]
  • [Cites] Cell. 1995 Dec 29;83(7):1101-11 [8548798.001]
  • [Cites] Nucleic Acids Res. 1995 Dec 11;23(23):4878-84 [8532532.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10750-8 [16322220.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17834-9 [17093053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18580-5 [17132729.001]
  • [Cites] Nucleic Acids Res. 2007;35(4):1098-107 [17264126.001]
  • [Cites] PLoS Comput Biol. 2007 Apr 6;3(4):e63 [17411336.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9375-88 [14645547.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2546-59 [14993291.001]
  • [Cites] J Cell Biochem. 2004 Apr 1;91(5):896-903 [15034925.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3459-71 [15213251.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6740-9 [15374992.001]
  • [Cites] Nucleic Acids Res. 2004;32(17):4955-61 [15388797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(10):3594-8 [2524830.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3260-5 [10737792.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Prostate. 2000 Jun 1;43(4):278-85 [10861747.001]
  • [Cites] Adv Cancer Res. 1996;68:109-82 [8712067.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):573-8 [8761372.001]
  • [Cites] Nucleic Acids Res. 1997 Mar 15;25(6):1108-16 [9092617.001]
  • [Cites] Diabetes. 1998 Jan;47(1):98-103 [9421381.001]
  • [Cites] Biochem Biophys Res Commun. 1998 May 29;246(3):668-74 [9618270.001]
  • [Cites] Dev Biol. 1998 Oct 15;202(2):183-95 [9769171.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1999;39:103-25 [10331078.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2916-24 [10378688.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2925-33 [10378689.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jun 24;260(1):216-21 [10381369.001]
  • [Cites] Mol Cell. 2004 Nov 19;16(4):521-35 [15546613.001]
  • [Cites] EMBO J. 2005 Jan 26;24(2):336-46 [15616584.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):382-90 [15778709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6902-6 [15867157.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2590-601 [15990869.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5490-502 [10891489.001]
  • [Cites] Oncogene. 2000 Jun 29;19(28):3200-12 [10918575.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5922-8 [11085504.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):281-3 [11125113.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):28-34 [11018030.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 15;29(2):397-406 [11139609.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Apr;280(4):L695-704 [11238010.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1383-93 [11250904.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2334-5 [11402330.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4984-94 [11526483.001]
  • [Cites] Oncogene. 2001 Dec 6;20(56):8116-24 [11781825.001]
  • [Cites] Nucleic Acids Res. 2001 Dec 15;29(24):4994-5000 [11812829.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):11617-20 [11805123.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):513-26 [11973610.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5757-9 [11983876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Development. 2002 Jun;129(11):2723-32 [12015299.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G266-9 [12121872.001]
  • [Cites] J Neurooncol. 2002 May;57(3):201-14 [12125983.001]
  • [Cites] Hum Mol Genet. 2002 Aug 1;11(16):1817-21 [12140184.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):166-74 [12185365.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):160-5 [12185367.001]
  • [Cites] J Biol Chem. 2002 Oct 4;277(40):36921-30 [12145275.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1315-23 [12368205.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7877-88 [12391156.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8300-8 [12501251.001]
  • (PMID = 18498649.001).
  • [ISSN] 1752-0509
  • [Journal-full-title] BMC systems biology
  • [ISO-abbreviation] BMC Syst Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2430022
  •  go-up   go-down


5. Mermershtain W, Vardi N, Gusakova I, Klein J: Serous papillary adenocarcinoma of the rete testis: unusual ultrasonography and pathological findings. J Cancer Res Ther; 2007 Jan-Mar;3(1):37-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma of the rete testis: unusual ultrasonography and pathological findings.
  • We report a case of serous papillary adenocarcinoma of the rete testis in a 22-year-old man.
  • Adenocarcinoma of the rete testis is highly resistant to radiotherapy and any known chemotherapeutic regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998718.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


6. Kondo N, Shiono Y, Yoshino Y, Sugaya S, Abe M, Koshitaka Y: [Papillary adenocarcinoma in a seminal vesicle cyst associated with contralateral renal agenesis: a case report]. Hinyokika Kiyo; 2007 Mar;53(3):175-8
Genetic Alliance. consumer health - Urogenital adysplasia, hereditary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary adenocarcinoma in a seminal vesicle cyst associated with contralateral renal agenesis: a case report].
  • We report a case of papillary adenocarcinoma inside a seminal vesicle cyst associated with contralateral renal agenesis in a 30-year-old man.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Cysts / diagnosis. Genital Neoplasms, Male / diagnosis. Kidney / abnormalities. Seminal Vesicles

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17447487.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Hirasaki S, Kanzaki H, Fujita K, Matsumura S, Matsumoto E, Yumoto E, Suzuki S: Papillary adenocarcinoma occurring in a gastric hyperplastic polyp observed by magnifying endoscopy and treated with endoscopic mucosal resection. Intern Med; 2008;47(10):949-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma occurring in a gastric hyperplastic polyp observed by magnifying endoscopy and treated with endoscopic mucosal resection.
  • Histological examination revealed that a part of the polyp surface was replaced with papillary adenocarcinoma.
  • Diagnosis of papillary adenocarcinoma in a hyperplastic polyp with mucosal invasion was made.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Polyps / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480580.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. González-Bosquet E, Suñol M, Morante D, Gomez Latre M, Callejo J, Lailla JM: Villoglandular papillary adenocarcinoma of the uterine cervix: a case report and literature review. Eur J Gynaecol Oncol; 2009;30(2):211-3
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix: a case report and literature review.
  • Villoglandular papillary adenocarcinoma is an infrequent form of well differentiated cervical papillary adenocarcinoma that has recently been described.
  • It usually affects young women and is distinguished from other adenocarcinomas by its generally good prognosis, since it infrequently invades the lymphovascular space.
  • We present a case of villoglandular papillary adenocarcinoma in a 28-year-old woman presenting risk factors for developing it: use of oral contraceptives, tobacco use, and infection with human papillomavirus types 16 and 33.
  • The presentation of this case provides an opportunity to review the literature on the diagnosis and treatment of villoglandular papillary adenocarcinoma, and the factors that may influence the prognosis of women diagnosed with this histological type of cervical cancer.
  • [MeSH-major] Adenocarcinoma, Papillary. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480259.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


9. Ilha MR, Loretti AP, Barros CS, Gimeno EJ, Martin CA: Papillary adenocarcinoma of the extrahepatic bile duct in a Holstein cow. Vet Pathol; 2005 Jan;42(1):74-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the extrahepatic bile duct in a Holstein cow.
  • Microscopically, the tumor was composed of well-differentiated, columnar epithelial cells with oval or round, vesicular, basal nuclei arranged in papillary projections.
  • The diagnosis of papillary adenocarcinoma of the extrahepatic bile duct was based on the morphologic features of the neoplasm and evidence of local invasion.
  • [MeSH-major] Adenocarcinoma, Papillary / veterinary. Bile Duct Neoplasms / veterinary. Bile Ducts, Extrahepatic / pathology. Cattle Diseases / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15657275.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


10. Dib N, Benhammou A, Meziane M, Harmouch A, Nazih N, Essakali L, Kzadri M, Sefiani S: [Papillary adenocarcinoma on ectopic thyroid tissue]. Ann Otolaryngol Chir Cervicofac; 2009 Apr;126(2):65-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary adenocarcinoma on ectopic thyroid tissue].
  • [Transliterated title] Adénocarcinome papillaire sur tissu thyroïdien ectopique.
  • OBJECTIVES: To report a case of papillary adenocarcinoma occurring on ectopic thyroid tissue in the hyoid bone region.
  • The pathologic study suggested a papillary adenocarcinoma on ectopic thyroid tissue.
  • CONCLUSIONS: Papillary adenocarcinoma on ectopic thyroid is a very rare situation.
  • Its diagnosis is histological.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Choristoma / pathology. Hyoid Bone / pathology. Thyroid Gland. Tongue Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Thyroidectomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296927.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Sillings CN, Weathers DR, Delgaudio JM: Thyroid-like papillary adenocarcinoma of the nasopharynx: a case report in a 19-year-old male. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Sep;110(3):e25-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for papillary adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid-like papillary adenocarcinoma of the nasopharynx: a case report in a 19-year-old male.
  • Primary thyroid-like papillary adenocarcinomas of the nasopharynx are rare, with only a limited number of cases reported in the literature.
  • In this article, we describe the case of a thyroid-like papillary adenocarcinoma of the nasopharynx in a 19-year-old male, with emphasis on clinical findings, histologic and immunohistochemical characteristics, and prognosis.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Carcinoma. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Thyroid Gland / pathology. Thyroid Neoplasms / pathology. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20727493.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Thyroid cancer, papillary
  •  go-up   go-down


12. Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Yoshikawa K, Sato Y, Aoyama H, Hayashi T, Kushima R: Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol; 2008 May;39(5):666-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
  • Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast have close histologic similarities.
  • We examined 23 serous papillary adenocarcinomas (16 ovarian, 5 endometrial, and 2 peritoneal) and 37 invasive micropapillary carcinomas of the breast (12 pure and 25 mixed types) on immunohistochemical expression of Wilm's tumor antigen-1 (WT1), CA125, and gross cystic disease fluid protein-15 (GCDFP-15), which have been reported to be useful in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
  • The positive rates of WT1, CA125, and GCDFP-15 in serous papillary adenocarcinomas were 78%, 78%, and 0%, respectively, and the corresponding rates in invasive micropapillary carcinomas were 3%, 40%, and 38%.
  • We consider CA125 to be not always useful in the differential diagnosis of serous papillary adenocarcinoma and invasive micropapillary carcinoma.
  • Although the positive rate of WT1 was significantly higher in serous papillary adenocarcinoma than in invasive micropapillary carcinoma, WT1 expression in endometrial serous papillary adenocarcinoma was infrequent (20%).
  • WT1 and GCDFP-15 could be useful markers for the differential diagnosis of ovarian and peritoneal serous papillary adenocarcinoma versus breast invasive micropapillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. CA-125 Antigen / analysis. Carrier Proteins / analysis. Endometrial Neoplasms / diagnosis. Genital Neoplasms, Female / diagnosis. Glycoproteins / analysis. Ovarian Neoplasms / diagnosis. WT1 Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18339419.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human; 0 / WT1 Proteins
  •  go-up   go-down


13. Rafee A, Prasad G, Phang S, Ramesh P: Aggressive digital papillary adenocarcinoma of the hand. J Hand Surg Eur Vol; 2007 Jun;32(3):275-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenocarcinoma of the hand.
  • This paper reports the case of a 26-year-old Caucasian male with an aggressive digital papillary adenocarcinoma of his right index finger.
  • Aggressive digital papillary adenocarcinoma is a rare tumour arising from sweat glands which occurs characteristically on the hands, fingers and toes.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Hand. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306428.001).
  • [ISSN] 1753-1934
  • [Journal-full-title] The Journal of hand surgery, European volume
  • [ISO-abbreviation] J Hand Surg Eur Vol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Nishimoto J, Amoh Y, Niiyama S, Takasu H, Katsuoka K: Aggressive digital papillary adenocarcinoma on the palm with pulmonary metastases. J Dermatol; 2008 Jul;35(7):468-70
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenocarcinoma on the palm with pulmonary metastases.
  • A 41-year-old Japanese male had aggressive digital papillary adenocarcinoma with pulmonary metastases.
  • On histopathological examination, the pulmonary biopsy specimens showed lobular proliferation of acantholytic tumor cells and some ductal structures associated with papillary projections.
  • The tumor was diagnosed as an aggressive digital papillary adenocarcinoma.
  • This report is a rare case of aggressive digital papillary adenocarcinoma that was diagnosed based on the histopathology of the pulmonary metastases, which showed ductal structures associated with papillary projections.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Lung Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705837.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Fu CH, Chang KP, Ueng SH, Wu CC, Hao SP: Primary thyroid-like papillary adenocarcinoma of the nasopharynx. Auris Nasus Larynx; 2008 Dec;35(4):579-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary thyroid-like papillary adenocarcinoma of the nasopharynx.
  • Thyroid-like papillary adenocarcinoma is an extremely rare neoplasm in the nasopharynx.
  • We present a case with a pedunculated tumor in the nasopharyngeal vault and the preoperative biopsy revealed a thyroid-like papillary adenocarcinoma.
  • Postoperative histopathological examinations and immunohistochemical studies confirmed the diagnosis.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Nasopharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Endoscopy. Humans. Male. Nasopharynx / pathology. Thyroid Neoplasms / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201851.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Furtado A, Nogueira R, Ferreira D, Tente D, Eisele R, Parente B: Papillary adenocarcinoma of the thymus: case report and review of the literature. Int J Surg Pathol; 2010 Dec;18(6):530-3
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the thymus: case report and review of the literature.
  • A 44-year-old male with a mediastinal mass measuring 3.5 × 3.5 × 3 cm was diagnosed with papillary adenocarcinoma of the thymus.
  • Other origins of papillary adenocarcinoma were excluded by clinical, imaging, and immunocytochemical methods before assuming this diagnosis.
  • He is alive after 24 months of follow-up with active disease.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18611939.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Burnell I, Tomkinson A, Hourihan M, Robinson M, Douglas-Jones A: Mucin-secreting papillary adenocarcinoma of the hyoid bone: a unique case. J Laryngol Otol; 2005 Jun;119(6):498-502
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-secreting papillary adenocarcinoma of the hyoid bone: a unique case.
  • We present a unique case of a mucin-secreting papillary adenocarcinoma of intestinal type which has invaded and completely destroyed the hyoid bone and metastasized to the cervical lymph nodes bilaterally.
  • The tumour is believed to have originated from a malignant thyroglossal duct remnant, and was managed with surgery and radiotherapy.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Head and Neck Neoplasms / pathology. Hyoid Bone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15992484.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 14
  •  go-up   go-down


18. Fancher TT, Dudrick SJ, Palesty JA: Papillary adenocarcinoma of the urachus presenting as an umbilical mass. Conn Med; 2010 Jun-Jul;74(6):325-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the urachus presenting as an umbilical mass.
  • The patient subsequently underwent a cystoscopic biopsy which was positive for papillary adenocarcinoma arising in a villous adenoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Urachus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20648839.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Imai T, Suga M, Kaimori M, Hiyama M, Yokoyama K, Kurotaki H: Peripheral pulmonary papillary adenocarcinoma with prominent cilia: report of a rare case that was difficult to diagnose preoperatively. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):949-57
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral pulmonary papillary adenocarcinoma with prominent cilia: report of a rare case that was difficult to diagnose preoperatively.
  • BACKGROUND: In pulmonary cytology, the existence of cilia is considered cytologic evidence of benign cells because it is generally considered that cilia could not be identified by light microscopic observation of pulmonary adenocarcinoma.
  • However, we encountered a rare exceptional case of pulmonary adenocarcinoma with cilia.
  • Histologically, the tumor was diagnosed as papillary adenocarcinoma with cilia and diffuse pleural dissemination was observed.
  • CONCLUSION: This rare case of peripheral pulmonary papillary adenocarcinoma with cilia could not be diagnosed as cancer cell on cytology.
  • Pulmonary papillary adenocarcinoma with cilia should be considered in the differential diagnosis of atypical cells in pulmonary cytology.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Cilia / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Preoperative Care
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Intraoperative Care. Lung / pathology. Middle Aged. Radiography, Thoracic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053576.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Bazil MK, Henshaw RM, Werner A, Lowe EJ: Aggressive Digital Papillary Adenocarcinoma in a 15-year-old Female. J Pediatr Hematol Oncol; 2006 Aug;28(8):529-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive Digital Papillary Adenocarcinoma in a 15-year-old Female.
  • Aggressive digital papillary adenocarcinoma is a rare neoplasm of eccrine sweat gland origin that typically presents as a mass on a finger, toe, or the adjacent skin.
  • We report a case of an aggressive digital papillary adenocarcinoma of the right second toe in a 15-year-old white female.
  • Two sentinel lymph nodes were biopsied and found to be negative for metastatic disease.
  • One year after surgery the patient has no evidence of disease recurrence.
  • To our knowledge, this is the youngest reported case of an aggressive digital papillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Fingers / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans. Rare Diseases. Sentinel Lymph Node Biopsy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912593.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ozbey C, Erdogan G, Pestereli HE, Simsek T, Karaveli S: Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case. APMIS; 2005 Oct;113(10):713-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case.
  • Surface epithelial-stromal cell tumors are the most common neoplasms of the ovary but occurrence of a serous adenocarcinoma and an adult granulosa cell tumor in the same ovary is an unusual incident.
  • Microscopy revealed an adult granulosa cell tumor and a serous papillary adenocarcinoma in the left ovary.
  • Immunohistochemical staining with inhibin alpha and pancytokeratin confirmed the diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] APMIS. 2007 Jun;115(6):769-71 [17550386.001]
  • (PMID = 16309432.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


22. Azumi M, Hou K, Numata A, Taniguchi N, Saga Y, Hashimoto H, Kakizaki H: Case report of renal pelvic adenocarcinoma associated with a renal stone that produced carbohydrate antigen 125 and carbohydrate antigen 19-9. Hinyokika Kiyo; 2007 Sep;53(9):631-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of renal pelvic adenocarcinoma associated with a renal stone that produced carbohydrate antigen 125 and carbohydrate antigen 19-9.
  • Pathological diagnosis was papillary adenocarcinoma of the renal pelvis with positive staining for carbohydrate antigen 125 (CA125) and carbohydrate antigen 19 9 (CA19-9).
  • Although papillary adenocarcinoma of the renal pelvis is extremely rare, the possibility of renal pelvic tumor should be kept in mind for patients who have a long-standing renal stone and hydronephrosis with irregularity at the renal pelvic wall.
  • [MeSH-major] Adenocarcinoma / immunology. CA-125 Antigen / analysis. CA-19-9 Antigen / analysis. Kidney Calculi / complications. Kidney Neoplasms / immunology. Kidney Pelvis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933139.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen
  •  go-up   go-down


23. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, Gerald WL, Travis WD: Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol; 2008 Jun;32(6):810-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.
  • The histologic heterogeneity of lung adenocarcinoma creates a variety of complex challenges to pathologists in analyzing the various subtypes.
  • The most common major histologic subtype was papillary (37%) followed by acinar (30%), solid (25%) and bronchioloalveolar (7%) carcinoma (BAC), although no pure BACs were seen.
  • Papillary adenocarcinoma strongly correlated with EGFR mutation (P<0.001) and gene profile Cluster 1 (P=0.006) with weaker correlations with low grade (P=0.038) and favorable behavior in Stage 1 patients (P=0.047).
  • Solid adenocarcinoma strongly correlated with gene profile Cluster 3 (P=0.001) and worse survival (P=0.001).
  • Cluster 1 correlated strongly with less smoking (P<0.001), papillary histology (P<0.001), and EGFR mutations (P<0.001).
  • Our data suggest that EGFR mutations are associated with papillary adenocarcinoma and gene profile Cluster 1.
  • As we do not know the major genetic pathways of 30% to 70% of lung adenocarcinomas, the comprehensive histologic subtyping we propose gives advantage for recognition of unanticipated histologic-genetic correlations that might not be detected using classification systems that focus primarily on specific aspects of adenocarcinomas such as BAC or EGFR mutations.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391747.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084999; United States / NCI NIH HHS / CA / UO1CA84999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Jian Z, Tomizawa Y, Yanagitani N, Iijima H, Sano T, Nakajima T: Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes. Pathol Int; 2005 Oct;55(10):619-25
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the lung is a more advanced adenocarcinoma than bronchioloalveolar carcinoma that is composed of two distinct histological subtypes.
  • To clarify the clinicopathological nature of papillary adenocarcinoma (PA) of the lung, 20 cases of PA were collected consecutively from resected adenocarcinoma of the lung, studied immunohistochemically and, using molecular techniques, compared with bronchioloalveolar carcinoma (BAC).
  • One of these subtypes was closely related to the morphology of BAC and might be diagnosed as adenocarcinoma with mixed subtypes.
  • The other PA subtype was composed of tall columnar cells and grew compressively, which was similar to type F adenocarcinoma previously reported by Noguchi et al.
  • Immunohistochemical studies using lung tissue-specific antigens, progression markers and tumor suppressor products found that PA seemed a more advanced adenocarcinoma than BAC, but no differences were observed among PA subtypes.
  • These findings suggest that PA is a more advanced adenocarcinoma subtype than BAC.
  • Further investigations are needed to clarify true PA as clinicopathologically and biologically independent from other histological subtypes of adenocarcinoma of the lung.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185291.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


25. Hasegawa I, Arimoto T, Yamada T, Komatani N, Hara H: [A case of non-mucin-producing papillary adenocarcinoma with a 19-year clinical history before operation]. Nihon Kokyuki Gakkai Zasshi; 2005 May;43(5):313-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of non-mucin-producing papillary adenocarcinoma with a 19-year clinical history before operation].
  • Despite examinations including bronchoscopy we could not make a definitive diagnosis.
  • The biopsy during the operation revealed adenocarcinoma and right upper lobectomy with nodal dissection was performed.
  • The ultimate diagnosis was non-mucin-producing papillary adenocarcinoma.
  • We reported this case because it was a rare slow-growing papillary adenocarcinoma that did not produce mucin and had a 19-year clinical history before operation.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Lung Neoplasms / surgery. Lymph Node Excision. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15969214.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


26. Kim ES, Lee DP, Lee MW, Choi JH, Moon KC, Koh JK: Cutaneous metastasis of uterine papillary serous carcinoma. Am J Dermatopathol; 2005 Oct;27(5):436-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of uterine papillary serous carcinoma.
  • Uterine papillary serous carcinoma (UPSC) is an uncommon highly malignant variant of endometrial adenocarcinoma that histologically and clinically resembles papillary serous carcinoma of the ovary.
  • This case demonstrates a very rare case of cutaneous metastasis of uterine papillary serous carcinoma.
  • A 54-year-old Korean female developed multiple pruritic skin nodules on the pubic area 13 months later after diagnosis of uterine papillary serous carcinoma.
  • A biopsy of the skin lesions showed papillary serous carcinoma, compatible with her primary tumor.
  • Without clinical history, it is difficult to distinguish other types of metastatic carcinoma to the skin and primary apocrine carcinoma of the skin from metastatic uterine papillary serous carcinoma.
  • Whereas uterine papillary serous carcinoma only rarely involves the skin, this entity should be included in the differential diagnosis of papillary adenocarcinoma in the skin.
  • [MeSH-major] Cystadenocarcinoma, Papillary / secondary. Skin Neoplasms / secondary. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148416.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Bhattacharya TK, Rani S, Maiti SK, Dayal S, Kumar P, Sharma A: Polymorphism of ZuBeCa3 microsatellite and its association with mammary tumor in dogs. Int J Immunogenet; 2007 Jun;34(3):161-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathological observation classified the cancer-affected animals into three groups namely, malignant solid mammary carcinoma, malignant papillary adenocarcinoma and benign papillary adenoma in which the frequency of A allele was relatively more predominant in benign tumor group, which is more than 80%.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Adenoma / genetics. Breast Neoplasms / genetics. Carcinoma / genetics. Microsatellite Repeats / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504505.001).
  • [ISSN] 1744-3121
  • [Journal-full-title] International journal of immunogenetics
  • [ISO-abbreviation] Int. J. Immunogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Adotey JM: Papillary adenocarcinoma of thyroid in a patient with right submandibular mass--a rare case of 'lateral aberrant thyroid'. Niger J Clin Pract; 2009 Sep;12(3):333-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of thyroid in a patient with right submandibular mass--a rare case of 'lateral aberrant thyroid'.
  • BACKGROUND: Ectopic thyroid is a rare entity in the study of thyroid disease.
  • AIM: To report a case of papillary adenocarcinoma of thyroid within a right submandibular mass in a 67-year-old man.
  • The FNAB showed papillary adenocarcinoma of the thyroid.
  • CONCLUSION: This patient illustrates the even rarer case of a 'lateral aberrant thyroid' presenting as a malignant submandibular mass.
  • [MeSH-major] Adenocarcinoma / diagnosis. Choristoma / diagnosis. Submandibular Gland Diseases / diagnosis. Thyroid Gland. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19803039.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


29. Miyoshi T, Shirakusa T, Ishikawa Y, Iwasaki A, Shiraishi T, Makimoto Y, Iwasaki H, Nabeshima K: Possible mechanism of metastasis in lung adenocarcinomas with a micropapillary pattern. Pathol Int; 2005 Jul;55(7):419-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible mechanism of metastasis in lung adenocarcinomas with a micropapillary pattern.
  • Micropapillary differentiation in adenocarcinomas has recently been associated with poor prognosis because these tumors are more likely to metastasize.
  • A case of primary lung adenocarcinoma with a prominent micropapillary pattern is presented here, with special reference to the immunohistochemical expression of the E-cadherin-mediated system and IQGAP1.
  • Histologically, the tumor was diagnosed as a moderately differentiated papillary adenocarcinoma, showing an extensive micropapillary pattern, with intrapulmonary metastases, pulmonary disseminations, lymphovascular invasions, and lymph node metastases.
  • This is the first report to suggest correlation between adenocarcinoma with a micropapillary pattern and the presence of adhesion molecules, and offers an intriguing first glimpse on the role of the micropapillary pattern in the process of metastasis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982217.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CTNNA1 protein, human; 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / IQ motif containing GTPase activating protein 1; 0 / Trans-Activators; 0 / alpha Catenin; 0 / beta Catenin; 0 / ras GTPase-Activating Proteins
  •  go-up   go-down


30. Tretheway D, Gebhardt JG, Dogra VS, Schiffhauer LM: Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature. Int J Gynecol Pathol; 2009 May;28(3):256-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic versus primary oncocytic papillary adenocarcinoma of the endometrium: a report of a case and review of the literature.
  • We report a case of an oncocytic papillary adenocarcinoma of the endometrium in an 89-year-old female with vaginal bleeding.
  • Diagnostic workup included an endometrial biopsy which showed malignant, oncocytic cells in a predominantly papillary pattern.
  • Consultation with experts in Gynecologic and Genitourinary pathology returned a diagnosis of "adenocarcinoma compatible with metastatic renal cell carcinoma"--an intriguing possibility worthy of further exploration.
  • To our knowledge, there are no reports in the literature of metastatic oncocytic papillary renal cell carcinoma to the endometrium.
  • The clinical and pathologic features of oncocytic papillary endometrial lesions, including primary and metastatic processes, are reviewed.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620943.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


31. Shimizu K, Itoh T, Shimizu M, Ku Y, Hori Y: CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas. Pancreas; 2009 Nov;38(8):e207-14
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas.
  • OBJECTIVES: The rate of intraductal papillary mucinous neoplasm (IPMN) progression is much slower than that of invasive ductal adenocarcinomas.
  • The identification of a clinicopathological marker to distinguish IPMNs from ductal adenocarcinomas is important for understanding the molecular mechanisms of pancreatic cancer.
  • METHODS: We examined the expression pattern of the cell surface marker CD133, which has been used to identify putative cancer stem cells from solid tumors, in adult pancreatic ductal adenocarcinomas (n = 10) and IPMNs (n = 34).
  • CD133 expression was also observed in ductal adenocarcinomas.
  • CONCLUSIONS: These results demonstrate that the expression of CD133 is down-regulated in IPMNs, suggesting that loss of CD133 expression might be a useful clinicopathological marker distinguishing IPMNs from ductal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Antigens, CD / biosynthesis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Glycoproteins / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pancreatic Ducts / chemistry. Pancreatic Ducts / pathology. Peptides. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786935.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


32. Sharma SG, Gokden M, McKenney JK, Phan DC, Cox RM, Kelly T, Gokden N: The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol; 2010 Dec;18(6):494-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
  • PAX-2, a homeogene expressed during kidney development, has been studied as a marker of renal origin in both primary and metastatic clear cell renal cell carcinoma (RCC), but not in papillary neoplasms or in comparison with RCC marker (RCCma).
  • We studied immunohistochemical expression of PAX-2 and RCCma in 24 papillary RCC (PRCC) and 66 nonrenal cell papillary neoplasms (NRCPN) from a variety of organs.
  • Of the NRCPN, 9/66 (14%) is positive for PAX-2 [4/10 (40%) ovarian papillary serous carcinomas, 5/9 (56%) uterine papillary serous carcinomas]; RCCma was positive in 28/66 (42%), including 9/9 (100%) papillary thyroid carcinomas, 8/10 (80%) ovarian papillary serous carcinomas, 4/9 (44%) uterine papillary serous carcinomas, 1/10 (10%) papillary urothelial carcinomas, 1/2 (50%) intraductal papillary mucinous carcinomas of the pancreas, 3/3 (100%) choroid plexus papillomas, 1/1 (100%) pituitary adenoma with papillary features, and 1/2 (50%) lung adenocarcinomas with papillary features.
  • PAX-2 and RCCma immunohistochemistry should be interpreted with caution in papillary neoplasms, with particular attention to the possibility of ovarian and uterine papillary serous carcinomas, which can express both PAX-2 and RCCma.
  • [MeSH-major] Advanced Glycosylation End Product-Specific Receptor / analysis. Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Renal Cell / chemistry. Carcinoma, Renal Cell / diagnosis. Immunohistochemistry. Kidney Neoplasms / chemistry. Kidney Neoplasms / diagnosis. PAX2 Transcription Factor
  • [MeSH-minor] Biopsy. Cell Nucleus / chemistry. Diagnosis, Differential. Female. Humans. Kidney / pathology. Neoplasm Metastasis. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21102195.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor
  •  go-up   go-down


33. Hsu HC, Ho CY, Chen CH, Yang CH, Hong HS, Chuang YH: Aggressive digital papillary adenocarcinoma: a review. Clin Exp Dermatol; 2010 Mar;35(2):113-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for papillary adenocarcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenocarcinoma: a review.
  • Vigorous treatment of aggressive digital papillary adenocarcinoma (ADPA), including amputation, has been recommended by most authors, but the appropriateness and effectiveness of excision as an alternative to amputation has not been systematically evaluated.
  • We also found that p63 may be a useful marker for distinguishing primary ADPA from metastatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma, Papillary. Amputation. Skin Neoplasms


34. Brody JR, Witkiewicz A, Williams TK, Kadkol SS, Cozzitorto J, Durkan B, Pasternack GR, Yeo CJ: Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Mod Pathol; 2007 Dec;20(12):1238-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia.
  • In this study, we evaluated pp32 protein expression in relation to the differentiation status of pancreatic ductal adenocarcinomas and precursor lesions of the pancreatic cancers. pp32 expression showed strong nuclear staining in normal pancreatic acini and ducts.
  • The intensity of this staining was maintained in pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms with mild dysplasia, well-differentiated adenocarcinomas, and in a subset of moderately differentiated adenocarcinomas. pp32 staining was absent or reduced in poorly differentiated tumors and in intraductal papillary mucinous neoplasms with moderate dysplasia.
  • We validated pp32 expression by a second technique, immunoblot analysis of lysates from resected pancreatic ductal adenocarcinomas and pancreatic cancer cell lines.
  • On the basis of this study and previous functional work that shows pp32 can inhibit K-ras transformation, we propose that reduction in pp32 expression levels may be a critical event in the progression of pancreatic tumorigenesis in an aggressive subset of pancreatic ductal adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / analysis. Gene Expression. Humans. Immunoblotting. Immunohistochemistry. Phosphoproteins / biosynthesis. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906614.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Phosphoproteins
  •  go-up   go-down


35. Abe T, Fukushima N, Brune K, Boehm C, Sato N, Matsubayashi H, Canto M, Petersen GM, Hruban RH, Goggins M: Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms. Clin Cancer Res; 2007 Oct 15;13(20):6019-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms.
  • EXPERIMENTAL DESIGN: Normal and neoplastic tissue DNA was isolated from fresh-frozen surgically resected tissues from 20 patients with primary familial pancreatic adenocarcinoma (defined as having at least one first-degree relative with pancreatic cancer), 31 with sporadic intraductal papillary mucinous neoplasms (IPMN), and 7 with familial IPMNs using laser capture microdissection.
  • Among the 20 primary familial pancreatic adenocarcinomas, we found a high prevalence of loss of heterozygosity (LOH) with an average fractional allelic loss (FAL) of 49.9% of an aggregate of 2,378 informative markers.
  • The level of FAL in the IPMNs (10%) was significantly lower than in the pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Papillary / genetics. Gene Expression Regulation, Neoplastic. Genome. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947463.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / P50 CA102701; United States / NCI NIH HHS / CA / R01 CA97075; United States / NCI NIH HHS / CA / R01 CA097075; United States / NHGRI NIH HHS / HG / N01-HG-65403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Tanno S, Nakano Y, Koizumi K, Sugiyama Y, Nakamura K, Sasajima J, Nishikawa T, Mizukami Y, Yanagawa N, Fujii T, Okumura T, Obara T, Kohgo Y: Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas; 2010 Jan;39(1):36-40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms.
  • OBJECTIVE: Although branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) are slow-growing tumors with a favorable prognosis, the synchronous occurrence of pancreatic ductal adenocarcinomas (PDAs) in patients with BD-IPMNs has been reported.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangiopancreatography, Magnetic Resonance. Disease Progression. Endosonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745777.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Riall TS, Stager VM, Nealon WH, Townsend CM Jr, Kuo YF, Goodwin JS, Freeman JL: Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. J Am Coll Surg; 2007 May;204(5):803-13; discussion 813-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas.
  • BACKGROUND: Recent small studies have reported an incidence of 23% to 39% for additional primary cancers in patients with intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
  • METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database (1983 to 1991), we identified all patients with primary pancreatic cancers (sporadic and adenocarcinomas arising in IPMNs).
  • We determined the incidence of additional primary cancers that developed either before or after the diagnosis of invasive IPMN and compared it to the incidence of additional primary cancers in patients with sporadic pancreatic adenocarcinoma.
  • Ten point three percent had one or more extra-pancreatic primary cancers in addition to their pancreatic primary (10.3% in patients with sporadic adenocarcinoma and 10.1% in patients with invasive IPMNs, p = NS).
  • In the 2,017 patients with additional primary cancer, 86% occurred before the diagnosis of pancreatic cancer and 14% occurred after the diagnosis of pancreatic cancer.
  • Although not as high as previously reported in smaller studies, the incidence is significant and comparable to the incidence seen in patients with adenocarcinoma.
  • Surveillance for other common malignancies in patients with IPMNs and pancreatic adenocarcinomas should be performed.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Carcinoma, Papillary / epidemiology. Neoplasms, Multiple Primary / epidemiology. Pancreatic Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481488.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Takai N, Hayashita C, Nakamura S, Narahara H, Matsumoto H: Villoglandular papillary adenocarcinoma of the uterine cervix diagnosed during pregnancy. Eur J Gynaecol Oncol; 2010;31(5):573-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix diagnosed during pregnancy.
  • Villoglandular papillary adenocarcinoma (VPA) is a very rare subtype of adenocarcinoma of the uterine cervix but a well recognized variant of cervical adenocarcinoma with a favorable prognosis generally occurring in women of child-bearing age.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Pregnancy Complications, Neoplastic / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


39. Kerr KM: Pulmonary adenocarcinomas: classification and reporting. Histopathology; 2009 Jan;54(1):12-27
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenocarcinomas: classification and reporting.
  • Pulmonary adenocarcinoma is the most common, and the most diverse form of primary lung carcinoma.
  • The current WHO classification of pulmonary adenocarcinoma does not adequately address a number of clinically relevant, biological factors.
  • The accurate diagnosis of adenocarcinoma on small biopsy specimens, accounting for most diagnoses of this disease, is challenged by the absence of tumour architecture in most samples.
  • Tumours showing a pure bronchioloalveolar (BAC) pattern are now best regarded as adenocarcinoma-in-situ; yet invasive adenocarcinomas may also show elements with the BAC pattern, dictating a better prognosis but biologically not necessarily in-situ disease.
  • Multifocal BAC-pattern adenocarcinoma still poses considerable conceptual and diagnostic problems.
  • In small tumours the papillary pattern, especially when micropapillary, confers a poor prognosis but this is not reflected in larger tumours.
  • It may therefore be possible to define a minimally invasive category of adenocarcinoma.
  • The rapid emergence of chemotherapeutic agents with histology-specific efficacy will increase the need for more accurate and specific diagnosis of adenocarcinoma on small samples.
  • Immunohistochemistry may help suggest this diagnosis when the features are non-specific but immunohistochemical findings are not diagnostic of this form of lung cancer.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187177.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Pineda-Daboin K, Neto A, Ochoa-Perez V, Luna MA: Nasopharyngeal adenocarcinomas: a clinicopathologic study of 44 cases including immunohistochemical features of 18 papillary phenotypes. Ann Diagn Pathol; 2006 Aug;10(4):215-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal adenocarcinomas: a clinicopathologic study of 44 cases including immunohistochemical features of 18 papillary phenotypes.
  • Nasopharyngeal adenocarcinomas (NPACs) are uncommon neoplasms with a diverse histomorphology and clinical behavior.
  • The purpose of our study was to better understand the clinicopathologic characteristics of NPACs and to identify the histologic and immunohistochemical features that distinguish the subtypes of papillary NPACs.
  • There were 28 salivary gland type, 13 conventional low-grade papillary NPACs of surface origin, and 3 metastatic adenocarcinomas, 2 thyroid and 1 lung.
  • We performed immunohistochemical studies in 18 papillary NPACs.
  • Two of the low-grade papillary NPACs simulated thyroid carcinoma; they expressed CK7, CK19, and TTF-1 but were negative for thyroglobulin.
  • Polymorphous low-grade papillary NPACs expressed diffuse reactivity to S-100, whereas low-grade papillary NPACs were negative or focally positive.
  • In contrast, 18 (64.2%) of the 28 patients with salivary gland-type NPACs had died of the disease or were living with disease at follow-up.
  • Papillary NPACs can be identified by their histology and selective immunohistochemical expression.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Immunoenzyme Techniques / methods. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Phenotype. Retrospective Studies. Salivary Glands / chemistry. Salivary Glands / pathology. Survival Rate. Thyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844563.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Maeda R, Isowa N, Onuma H, Miura H, Harada T, Touge H, Tokuyasu H, Kawasaki Y: Lung adenocarcinomas with micropapillary components. Gen Thorac Cardiovasc Surg; 2009 Oct;57(10):534-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung adenocarcinomas with micropapillary components.
  • PURPOSE: Micropapillary adenocarcinoma is becoming increasingly recognized as a prognostically important histological subtype of carcinoma in various organs.
  • This report presents the clinicopathological findings of lung adenocarcinomas with micropapillary components.
  • Seven patients are alive without disease, whereas seven are alive with disease and one patient died of disease.
  • Surgeons should search more carefully for metastases and conduct a closer follow-up on these patients when this feature is present with lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19830516.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Hunter JB, Smith RV, Brandwein-Gensler M: Low-grade papillary adenocarcinoma of the palate: the significance of distinguishing it from polymorphous low-grade adenocarcinoma. Head Neck Pathol; 2008 Dec;2(4):316-23
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade papillary adenocarcinoma of the palate: the significance of distinguishing it from polymorphous low-grade adenocarcinoma.
  • Low-grade papillary adenocarcinoma (LGPA) represents a relatively rare histological variant of polymorphous low-grade adenocarcinoma (PLGA).
  • However, as uniform diagnostic criteria are lacking, we suggest a cut-off value of 10% or greater papillary formation as being necessary to separate LGPA from PLGA.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Palatal Neoplasms / diagnosis. Palate, Hard / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dentomaxillofac Radiol. 2001 May;30(3):184-7 [11420633.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):207-19 [10421256.001]
  • [Cites] Histopathology. 1998 Jun;32(6):521-9 [9675591.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):805-10 [15944978.001]
  • [Cites] Laryngoscope. 2006 Dec;116(12):2145-9 [17146387.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] J Korean Med Sci. 2007 Apr;22(2):373-6 [17449954.001]
  • [Cites] Radiother Oncol. 1999 Aug;52(2):165-71 [10577702.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Sep;123(3):337-8 [10964318.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1319-28 [11023093.001]
  • [Cites] J Clin Pathol. 2000 Dec;53(12):942-5 [11265182.001]
  • [Cites] Histopathology. 2002 Sep;41(3):250-9 [12207787.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7 [14623749.001]
  • [Cites] Histopathology. 2004 Feb;44(2):164-71 [14764060.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):287-92 [15306944.001]
  • [Cites] Cancer. 1974 Jan;33(1):153-8 [4810090.001]
  • [Cites] J Laryngol Otol. 1983 Sep;97(9):825-35 [6886543.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Aug;56(2):157-66 [6578478.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):935-42 [6692293.001]
  • [Cites] Am J Surg Pathol. 1984 May;8(5):367-74 [6731663.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1985 Oct;60(4):387-95 [3864098.001]
  • [Cites] J Craniomaxillofac Surg. 1987 Dec;15(6):359-64 [2828432.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Sep;66(3):323-33 [2845326.001]
  • [Cites] Br J Oral Maxillofac Surg. 1989 Dec;27(6):494-500 [2688740.001]
  • [Cites] J Laryngol Otol. 1991 Apr;105(4):309-11 [2026950.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Jun;50(6):595-600 [1593320.001]
  • [Cites] J Oral Pathol Med. 1993 Aug;22(7):327-30 [8229870.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Jan;77(1):41-7 [8108096.001]
  • [Cites] Thorac Cardiovasc Surg. 1995 Jun;43(3):178-80 [7570572.001]
  • [Cites] J Laryngol Otol. 1995 Dec;109(12):1222-5 [8551165.001]
  • [Cites] Int J Oral Maxillofac Surg. 1996 Feb;25(1):40-4 [8833299.001]
  • [Cites] Am J Clin Pathol. 1999 Jun;111(6):785-91 [10361514.001]
  • (PMID = 20614302.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2807587
  • [Keywords] NOTNLM ; Low-grade papillary adenocarcinoma / Oral salivary gland tumor / Polymorphous low-grade adenocarcinoma
  •  go-up   go-down


43. Yousuf K, Archibald SD: Brain metastases from papillary adenocarcinoma of the thyroid. J Otolaryngol; 2006 Dec;35(6):366-72
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from papillary adenocarcinoma of the thyroid.
  • BACKGROUND: Papillary thyroid adenocarcinoma (PTA) is the most common type of thyroid malignancy.
  • We present a series of four patients with this development and review their diagnosis and treatment.
  • All patients eventually died of their disease, and the overall survival after the diagnosis of brain metastases was 15.3 months in the four patients.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Brain Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380829.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


44. Korach J, Machtinger R, Perri T, Vicus D, Segal J, Fridman E, Ben-Baruch G: Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge. Acta Obstet Gynecol Scand; 2009;88(3):355-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge.
  • Villoglandular papillary adenocarcinoma (VGA) is a rare subtype of cervical adenocarcinoma.
  • The aim of our study was to evaluate the reliability of histological assessment for pre-treatment diagnosis of VGA.
  • Median age at diagnosis was 38.8 years (range 27-65).
  • Of these, only two had been correctly diagnosed preoperatively, while in three, the initial biopsies were benign or pre-malignant.
  • In four patients, the biopsy results had been interpreted as an invasive malignant tumor necessitating hysterectomy.
  • The final histological report on the remaining three patients was invasive cervical adenocarcinoma.
  • We conclude that pre-treatment diagnosis should not be based solely on a simple punch biopsy because of its low rate of diagnostic accuracy.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


45. Ikeda M, Yanagisawa A, Seki M, Sasaki K, Takano K, Kato Y: The early state of invasive pancreatic ductal adenocarcinomas: characteristics of the low papillary type and flat type intraductal carcinoma. Pancreas; 2006 Aug;33(2):135-41
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The early state of invasive pancreatic ductal adenocarcinomas: characteristics of the low papillary type and flat type intraductal carcinoma.
  • RESULTS: Histologically, the noninvasive cancer parts were categorized into 3 types: flat (F), low papillary (LP), and mixed (flat and low papillary [FLP]) types; each type comprised 18.3%, 34.1%, and 47.6%, respectively.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868478.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Nagai N, Hirata E, Kusuda T, Mukai K, Arihiro K, Ohama K: Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1187-90
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report.
  • Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported.
  • Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343210.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


47. Rubesa-Mihaljević R, Vrdoljak-Mozetic D, Ostojić DV, Stemberger-Papić S, Sindik N, Krasević M: Villoglandular papillary adenocarcinoma of the uterine cervix with aggressive clinical course--a case report. Coll Antropol; 2010 Mar;34(1):291-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix with aggressive clinical course--a case report.
  • Villoglandular papillary adenocarcinoma (VGA) of cervix is an uncommon but well recognized histologic subtype of cervical adenocarcinoma which usually affects young women.
  • We present a case of a 22-year-old woman admitted at our Department for glandular abnormality on cervical smear and episodes of vaginal discharge.
  • In the Pap smear, the cytological features were suspicious but not diagnostic of adenocarcinoma, therefore reported as atypical glandular cells (AGC).
  • Cervical smears examination would be helpful for an early diagnosis of VGA, however the cytologic recognition is often difficult.
  • Further investigation of the pathogenesis, diagnosis and therapy of the tumor is needed.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Severity of Illness Index. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437645.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


48. Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu LS, Ronnett BM: Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol; 2009 Oct;33(10):1504-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
  • Uterine serous carcinomas typically have a characteristic morphology (papillary architecture, high-grade nuclei) and immunoprofile (diffuse/strong p53 expression, loss of hormone receptor expression) that distinguish them from most endometrial endometrioid carcinomas.
  • P16 expression patterns distinguish endometrioid carcinomas (patchy) from human papillomavirus (HPV)-related endocervical adenocarcinomas (diffuse/strong) but utility for distinction of serous carcinomas from endometrioid carcinomas and endocervical adenocarcinomas has not been evaluated in a large series.
  • Immunohistochemical analysis of p16 expression was performed on 201 uterine and endocervical adenocarcinomas in hysterectomy specimens, including 49 serous carcinomas, 101 endometrial endometrioid carcinomas (44 FIGO grade 1, 40 FIGO grade 2, and 17 FIGO grade 3), and 51 HPV-related endocervical adenocarcinomas.
  • Similar to serous carcinomas, all endocervical adenocarcinomas exhibited diffuse/moderate-strong p16 expression, with percentage of positive tumor cells ranging from 90% to 100% (mean/median: 94%/90%).
  • Distinction of serous carcinomas from endocervical adenocarcinomas (HPV-related type), both of which share diffuse p16 expression and frequently lack hormone receptor expression, relies on morphology and diffuse/strong p53 expression in the former and detection of HPV in the latter.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cystadenocarcinoma, Serous / diagnosis. Endometrial Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] DNA Mutational Analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Papillomavirus Infections / complications. Papillomavirus Infections / diagnosis. Papillomavirus Infections / metabolism. Polymerase Chain Reaction. Tumor Suppressor Protein p53 / genetics. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623034.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


49. Onishi T, Franco OE, Shibahara T, Arima K, Sugimura Y: Papillary adenocarcinoma of the renal pelvis and ureter producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125. Int J Urol; 2005 Feb;12(2):214-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma of the renal pelvis and ureter producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125.
  • We report a case of advanced renal pelvis and ureter adenocarcinoma producing carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125).
  • Biopsy of the ureteral mass revealed papillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / immunology. Antigens, Neoplasm / metabolism. Kidney Neoplasms / immunology. Ureteral Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15733120.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


50. Kondo T, Nakazawa T, Murata S, Katoh R: Stromal elastosis in papillary thyroid carcinomas. Hum Pathol; 2005 May;36(5):474-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal elastosis in papillary thyroid carcinomas.
  • Stromal elastosis, defined as dense aggregations of elastic fibers, is found in some neoplastic tissues especially in malignant tumors of the breast and lung.
  • Stromal elastosis was found in 66% of papillary thyroid carcinomas (PTCs), although it was not identified in other histological types of thyroid neoplasms.
  • The frequency of stromal elastosis in PTCs was very similar to the frequencies in breast and lung adenocarcinomas, and higher than the frequencies in carcinomas of other organs.
  • In conclusion, our results suggest that stromal elastosis is a characteristic histological finding of PTCs, presumably associated with their growth pattern and/or histological architecture.
  • It is, therefore, reasonable to propose that stromal elastosis is an ancillary feature in the histopathological diagnosis of PTCs.
  • [MeSH-major] Carcinoma, Papillary / pathology. Elastic Tissue / pathology. Stromal Cells / pathology. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948113.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Nofech-Mozes S, Rasty G, Ismiil N, Covens A, Khalifa MA: Immunohistochemical characterization of endocervical papillary serous carcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:286-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical characterization of endocervical papillary serous carcinoma.
  • Endocervical adenocarcinomas are rare and aggressive neoplasms.
  • Papillary serous endocervical adenocarcinomas are the rarest form of endocervical adenocarcinomas.
  • This tumor exhibits morphologic similarities to its counterparts commonly seen in the endometrium, fallopian tubes, ovaries, and peritoneum, which are known to have an aggressive behavior.
  • In this study, we included ten cases of papillary serous carcinomas arising from the uterine cervix (PSCC) diagnosed in the absence of a primary endometrial malignancy.
  • We studied their immunohistochemical profile, using a panel of antibodies against Ki67, bcl-2, p53, carcinoembryonic antigen (CEA), and CD10, and compared them to 20 consecutive cases of cervical adenocarcinoma of conventional cell subtypes (CAC) (15 mucinous, 3 adenosquamous, and 2 endometrioid).
  • PSCC is a distinctive immunophenotypic subtype of endocervical adenocarcinoma with significantly higher p53 and lower CEA reactivity than other more common histologic subtypes.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515605.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


52. Chilosi M, Murer B: Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med; 2010 Jan;134(1):55-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy.
  • CONTEXT: Lung cancer is one of the most frequent and lethal malignant neoplasms, but knowledge regarding the molecular basis of its pathogenesis is far from complete due to the striking diversity of different forms.
  • The current lung cancer classification (World Health Organization 2004) can efficiently distinguish clinically relevant major subtypes (small cell and non-small cell carcinomas), but its results are partly inadequate when facing prognostic and therapeutic decisions for non-small cell carcinomas, especially for the group of tumors classified as adenocarcinoma.
  • Lung adenocarcinoma comprises a heterogeneous group of tumors characterized by diverse morphologic features and molecular pathogenesis.
  • The category of mixed adenocarcinomas includes most adenocarcinomas (approximately 80%) and, according to World Health Organization criteria, is defined by the occurrence of a mixed array of different patterns (acinar, papillary, bronchioloalveolar, solid with mucin).
  • The histologic recognition of mixed adenocarcinoma is subjective and cannot consistently discriminate between responders and nonresponders to new targeted therapies (eg, tyrosine kinase inhibitors).
  • In this evolving scenario, pathologists face new challenging diagnostic roles that include not only the precise morphologic definition of carcinoma subtypes but also their molecular characterization.
  • OBJECTIVE: To use a comprehensive critical analysis reconciling the overwhelming variety of biologic, morphologic, molecular, and clinical data to define new classification schemes for lung adenocarcinoma.
  • CONCLUSIONS: A new classification approach should redefine lung adenocarcinoma heterogeneity reconciling classic morphology, immunophenotypic and molecular features of neoplastic cells, and also relevant information provided by stem cell biology.
  • This approach, which has been already successfully applied in World Health Organization classification of other tumors, could improve the recognition of new reproducible profiles for adenocarcinomas, more closely and reproducibly related to clinical features and response to specific therapies, limiting the use of "wastebasket" categories such as mixed adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073606.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Lara C, Porras V, Jurado P, Gómez A, Arredondo F: [Papillary urothelial carcinoma of the urachus]. Arch Esp Urol; 2006 Nov;59(9):914-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary urothelial carcinoma of the urachus].
  • [Transliterated title] Carcinoma papilar urotelial de uraco.
  • The pathologic lesions of the urachus include benign and malignant neoplasms.
  • The majority of malignant urachal neoplasms are adenocarcinomas.
  • METHODS AND RESULTS: We report a case of papillary urothelial carcinoma of urachus in a 73-year-old woman.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Urachus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190218.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


54. Chantranuwat C, Sriuranpong V, Huapai N, Chalermchai T, Leungtaweeboon K, Voravud N, Mutirangura A: Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation. J Med Assoc Thai; 2005 Sep;88 Suppl 4:S322-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation.
  • Almost the mutations were present in adenocarcinomas.
  • Few had studied on histopathologic correlation with EGFR mutation in pulmonary adenocarcinomas.
  • To obtain better view on pathobiology of pulmonary adenocarcinomas, we correlated exons 19 and 21 mutations with various histopathologic features by dissecting particular histological patterns from 60 surgically resected adenocarcinomas.
  • EGFR-mutated tumors comprised less proportion of papillary pattern than tumors without mutation (mean = 1.5% vs. 11.2%, p = 0.049).
  • CONCLUSION: High frequency of the mutation does not present only in BAC pattern, but also in well-formed and poorly-formed acinar patterns, suggesting them as usual spectrum of EGFR mutated adenocarcinomas.
  • Other characteristics of EGFR-mutated adenocarcinomas include TRU-type histology, smaller size, and less solid phenotype.
  • [MeSH-major] Adenocarcinoma / pathology. Genes, erbB-1 / genetics. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623049.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


55. Korinth D, Pacyna-Gengelbach M, Deutschmann N, Hattenberger S, Bockmühl U, Dietel M, Schroeder HG, Donhuijsen K, Petersen I: Chromosomal imbalances in wood dust-related adenocarcinomas of the inner nose and their associations with pathological parameters. J Pathol; 2005 Oct;207(2):207-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal imbalances in wood dust-related adenocarcinomas of the inner nose and their associations with pathological parameters.
  • Comparative genomic hybridization (CGH) was used to screen 42 wood dust-related sinonasal adenocarcinomas for chromosomal alterations.
  • The tumour collection comprised 39 papillary-tubular cylinder cell adenocarcinomas (PTCCs; six cases G1, 23 G2, and ten G3), two alveolar goblet cell adenocarcinomas (AGCs), and one signet ring cell adenocarcinoma (SRC), according to the Kleinsasser and Schroeder classification.
  • These data provide further evidence for a recurrent pattern of chromosomal imbalances in sinonasal adenocarcinomas and highlight distinct aberrations that are associated with tumour differentiation and progression.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Occupational Diseases / genetics. Paranasal Sinus Neoplasms / genetics. Wood
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / etiology. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / etiology. Carcinoma, Signet Ring Cell / genetics. Carcinoma, Signet Ring Cell / pathology. Cell Differentiation / physiology. DNA, Neoplasm / genetics. Dust. Humans. Male. Middle Aged. Nucleic Acid Hybridization / methods. Occupational Exposure / adverse effects

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16041693.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Dust
  •  go-up   go-down


56. Matsuda M, Amemiya H, Kono H, Suzuki T, Chang MS, Izawa S, Furuya S, Takano A, Matsumoto Y, Fujii H: A huge primary peritoneal papillary adenocarcinoma which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor: report of a case. Surg Today; 2005;35(2):175-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A huge primary peritoneal papillary adenocarcinoma which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor: report of a case.
  • We herein report a 69-year-old woman who presented with a huge intra-abdominal tumor which demonstrated imaging findings similar to those of extrahepatic-growing type hepatic tumor, but turned out to be primary peritoneal papillary adenocarcinoma.
  • A fine-needle aspiration biopsy of the tumor showed poorly differentiated adenocarcinoma of unknown origin.
  • Histological and immunohistochemical examinations demonstrated the tumor to be primary peritoneal papillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / radiography. Liver Neoplasms / radiography. Peritoneal Neoplasms / radiography
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Diagnosis, Differential. Female. Fluorouracil / therapeutic use. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674505.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


57. Lee J, Jeon YH, Lee S: Papillary adenocarcinoma arising in a duplication of the cecum. Abdom Imaging; 2008 Sep-Oct;33(5):601-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma arising in a duplication of the cecum.
  • Malignant carcinomatous change is a rare complication in an enteric duplication cyst, and papillary adenocarcinoma is especially unusual.
  • We describe a papillary adenocarcinoma, arising from a duplication of the colon, seen as a cyst with an enhancing papillary projection nodule located adjacent to the wall of the ascending colon and cecum on computed tomography.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Cecal Neoplasms / diagnosis. Cecum / abnormalities
  • [MeSH-minor] Adult. Cecal Diseases / pathology. Colectomy / methods. Colonoscopy. Cysts / pathology. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912582.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Fatima S, Ahmad Z, Qureshi A, Minhas K, Pal I: Minimally invasive papillary carcinoma of the extrahepatic bile ducts. J Coll Physicians Surg Pak; 2008 Oct;18(10):649-51
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive papillary carcinoma of the extrahepatic bile ducts.
  • Invasive papillary carcinomas of the Extrahepatic Bile Ducts (EBD) are uncommon (4-5%).
  • The course is less aggressive than conventional adenocarcinomas of the extrahepatic bile ducts.
  • Non-invasive and minimally invasive papillary carcinomas are even rarer, behave as in-situ carcinomas and are associated with excellent long-term prognosis.
  • A variety of lesions of the EBD that show papillary architecture should be distinguished from papillary carcinoma.
  • Here, we report a case of papillary carcinoma of the common bile duct showing minimal invasion.
  • Separation of invasive from non-invasive or minimally invasive papillary carcinoma is critical in estimating the patient outcome.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic. Carcinoma, Papillary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940127.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


59. Gorva AD, Mohil R, Srinivasan MS: Aggressive digital papillary adenocarcinoma presenting as a paronychia of the finger. J Hand Surg Br; 2005 Oct;30(5):534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenocarcinoma presenting as a paronychia of the finger.
  • Aggressive digital papillary adenocarcinoma is a rare skin adnexal tumour, which has a predilection for the digits.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Fingers / pathology. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Paronychia / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055244.001).
  • [ISSN] 0266-7681
  • [Journal-full-title] Journal of hand surgery (Edinburgh, Scotland)
  • [ISO-abbreviation] J Hand Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


60. Takai N, Hayashita C, Nakamura S, Narahara H, Matsumoto H: A Case of Villoglandular Papillary Adenocarcinoma of the Uterine Cervix Diagnosed during Early Pregnancy Followed by Successful Term Delivery. Case Rep Med; 2010;2010:314547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Villoglandular Papillary Adenocarcinoma of the Uterine Cervix Diagnosed during Early Pregnancy Followed by Successful Term Delivery.
  • Villoglandular papillary adenocarcinoma (VPA) is a very rare subtype of adenocarcinoma of the uterine cervix, but a well-recognized variant of cervical adenocarcinoma with a favorable prognosis and generally occurring in women of child-bearing age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1989 May 1;63(9):1773-9 [2702584.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 2):906-8 [7724158.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):1-7 [8418074.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):147-52 [8995564.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):310-3 [11330967.001]
  • [Cites] J Med Assoc Thai. 2001 Jun;84(6):882-8 [11556470.001]
  • [Cites] Eur J Surg Oncol. 2008 May;34(5):606-8 [17643913.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):64-70 [14751140.001]
  • [Cites] Tohoku J Exp Med. 2004 Apr;202(4):305-10 [15109129.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):883-7 [16088403.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):192-4 [16266744.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):168-71 [16325894.001]
  • [Cites] BJOG. 2003 Jun;110(6):627-9 [12798484.001]
  • (PMID = 20589215.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2892664
  •  go-up   go-down


61. Falcón O, García R, Lubrano A, Morín JC, Andujar M: Successful term delivery following conservative management for villoglandular papillary adenocarcinoma of the uterine cervix: A case report. Gynecol Oncol; 2006 Apr;101(1):168-71
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful term delivery following conservative management for villoglandular papillary adenocarcinoma of the uterine cervix: A case report.
  • BACKGROUND: Villoglandular papillary adenocarcinoma (VPA) is a rare subtype of adenocarcinoma of the uterine cervix.
  • CASE: A 34-year-old asymptomatic woman was diagnosed of a well-differentiated VPA without extracervical spread of the disease.
  • Last control 8 years later showed no evidence of disease.
  • [MeSH-major] Carcinoma, Papillary / surgery. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325894.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Mori Y, Ohtsuka T, Tsutsumi K, Yasui T, Sadakari Y, Ueda J, Takahata S, Nakamura M, Tanaka M: Multifocal pancreatic ductal adenocarcinomas concomitant with intraductal papillary mucinous neoplasms of the pancreas detected by intraoperative pancreatic juice cytology. A case report. JOP; 2010;11(4):389-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal pancreatic ductal adenocarcinomas concomitant with intraductal papillary mucinous neoplasms of the pancreas detected by intraoperative pancreatic juice cytology. A case report.
  • CONTEXT: Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas have been detected with increasing frequency as a result of the progression of diagnostic modalities.
  • During a follow-up for branch duct IPMNs, a stenotic lesion of the main duct in the pancreatic body was found by ERCP, and brush cytology of the stenosis revealed an adenocarcinoma.
  • A distal pancreatectomy was proposed; however, intraoperative pancreatic juice cytology from the pancreatic head also revealed adenocarcinoma, and a total pancreatectomy was finally carried out.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Juice / cytology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601817.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Srilatha PS, Roy A: Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature. Indian J Pathol Microbiol; 2007 Oct;50(4):819-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature.
  • Well differentiated villoglandular adenocarcinoma of uterine cervix is a rare tumour which usually occurs in young women.
  • Histopathological findings were consistent with villoglandular papillary adenocarcinoma associated with high grade cervical intraepithelial neoplasia (CIN-3).
  • A review of literature showed that only occasional cases showing disease spread have been reported, suggesting caution in the management and regular follow up of the patient.
  • [MeSH-major] Adenocarcinoma, Papillary / complications. Adenocarcinoma, Papillary / pathology. Cervical Intraepithelial Neoplasia / complications. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology


64. Krishnamurthy J, Patil B: Aggressive digital papillary adenocarcinoma diagnosed by fine needle aspiration cytology. J Cytol; 2010 Jul;27(3):109-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenocarcinoma diagnosed by fine needle aspiration cytology.
  • Aggressive digital papillary adenocarcinoma is a rare variant of eccrine sweat gland malignancy with a propensity for metastases and recurrence.
  • We report a 45-year-old female with aggressive digital papillary adenocarcinoma diagnosed by fine needle aspiration cytology (FNAC).
  • The recognition of aggressive digital papillary adenocarcinoma as a distinct clinicopathological eccrine sweat gland neoplasm is important because of the potential for aggressive local growth and distant metastasis.
  • FNAC plays an important role in the preoperative diagnosis and management of these lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187879.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2983077
  • [Keywords] NOTNLM ; Aggressive digital papillary adenocarcinoma / eccrine sweat gland tumor / fine needle aspiration cytology
  •  go-up   go-down


65. Trevino JG, Espat NJ, Helton WS: Intraductal papillary mucinous neoplasms of the pancreas. Curr Treat Options Gastroenterol; 2006 Sep;9(5):385-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas.
  • Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are rare tumors with different characteristics than conventional ductal pancreatic adenocarcinomas.
  • Once IPMN is diagnosed, treatment strategies are based upon multiple factors, including patient condition, symptoms, and type and extent of disease.
  • Although these factors may determine different treatment strategies, surgery remains the mainstay of therapy due to the favorable survival rate if the disease is diagnosed and treated prior to the development of invasive carcinoma.
  • The goal of treatment is to alleviate symptoms and to extirpate disease prior to its transition to malignancy, invasion, and metastases.
  • Although some experts advocate a nonoperative approach to patients with suspected benign disease, the risk of progression to malignancy can present a dilemma for the treating physician and patient.
  • Unfortunately, differentiation of benign from malignant disease can only be determined conclusively following complete review of the entire surgical specimen.
  • To further complicate treatment strategies, IPMN is a multifocal disease, and additional lesions can develop in the remnant pancreas.
  • This fact has compelled most physicians familiar with the disease to institute lifelong surveillance for patients with the disease.
  • Although our understanding of IPMN has increased greatly since its initial description in 1982, the natural history of the disease is poorly defined, and there is no consensus among experts on standards of practice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16942663.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Al-Refaie WB, Choi EA, Tseng JF, Tamm EP, Lee JH, Lee JE, Evans DB, Pisters PW: Intraductal papillary mucinous neoplasms of the pancreas. Med Princ Pract; 2006;15(4):245-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas.
  • The introduction of the exocrine pancreatic classification by the World Health Organization and improvements in pancreatic imaging have led to an improved understanding of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
  • As a result, IPMNs of the pancreas are increasingly being recognized as a separate disease entity.
  • IPMNs are characterized by the cystic dilatation of the pancreatic duct and its branches, with papillary projections.
  • The lymph nodes are involved considerably less frequently than they are in pancreatic adenocarcinoma.
  • Most patients are symptomatic at diagnosis and require a diagnostic workup similar to that for patients with pancreatic adenocarcinoma.
  • Unlike ductal adenocarcinomas, IPMNs follow a relatively indolent course; the 5-year survival rate in patients with invasive IPMNs is 57%.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16763389.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 29
  •  go-up   go-down


67. Ouaïssi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, Payan MJ, Dahan L, Pirrò N, Seitz JF, Mas E, Lombardo D, Ouaissi A: High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol; 2008 Aug;15(8):2318-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas.
  • METHODS: Total RNA was isolated from 11 pancreatic adenocarcinomas (PA): stage 0 (n = 1), IB (n = 1), IIB (n = 6), III (n = 1), IV (n = 2), one serous cystadenoma (SC), one intraductal papillary mucinous tumor of the pancreas (IMPN), one complicating chronic pancreatitis (CP), and normal pancreas (NP) obtained during donor liver transplantation.
  • [MeSH-major] Adenocarcinoma / enzymology. Gene Expression Regulation, Enzymologic. Histone Deacetylases / metabolism. Pancreatic Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506539.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; EC 3.5.1.98 / HDAC7 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


68. Kanoh A, Seko A, Ideo H, Yoshida M, Nomoto M, Yonezawa S, Sakamoto M, Kannagi R, Yamashita K: Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. Glycoconj J; 2006 Jul;23(5-6):453-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.
  • Mucinous and clear cell adenocarcinomas are the major histological types of ovarian epithelial cancer and are associated with a poor prognosis due to their resistance to chemotherapy.
  • A novel tumor marker specific for ovarian mucinous and clear cell adenocarcinomas would be helpful for overcoming these serious diseases.
  • We showed previously by enzymological characterization and RT-PCR that colonic mucinous adenocarcinoma tissues ectopically express GlcNAc6ST-2, a member of the carbohydrate 6-O-sulfotransferase family (Seko, A. et al. (2002) Glycobiology 12, 379-388).
  • Here, we prepared a GlcNAc6ST-2-specific polyclonal antibody for immunohistochemical analysis and found that GlcNAc6ST-2 is ectopically expressed by not only colonic mucinous adenocarcinomas but also ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • In contrast, solid serous adenocarcinomas, endometrioid adenocarcinomas, and mucinous adenomas expressed GlcNAc6ST-2 much less frequently or not at all.
  • RT-PCR analysis confirmed that GlcNAc6ST-2 transcripts are expressed in ovarian mucinous adenocarcinomas but not in mucinous adenomas.
  • In addition, immunohistochemical analysis using sulfated glycan-specific monoclonal antibodies showed that ovarian adenocarcinoma cells express GlcNAc 6-O-sulfated glycans, including an L-selectin ligand and its related glycans.
  • These results indicate that GlcNAc6ST-2 would be a novel tumor antigen that is specifically expressed in ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Drug Resistance, Neoplasm / physiology. Ovarian Neoplasms / enzymology. Sulfotransferases / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897186.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.- / carbohydrate sulfotransferases
  •  go-up   go-down


69. Caruso RA, Basile G, Crisafulli C, Pizzi G, Finocchiaro G, Fedele F, Paparo D, Parisi A: Granulomatous inflammatory reaction in human gastric adenocarcinomas: a light and electron microscopy study. Ultrastruct Pathol; 2009 Dec;33(6):269-73
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulomatous inflammatory reaction in human gastric adenocarcinomas: a light and electron microscopy study.
  • The authors report 9 cases of papillary-tubular gastric adenocarcinomas characterized by mature granulomas associated with recent microhemorrhages.
  • This study provides morphological examples of skewed type II macrophage infiltration in gastric adenocarcinomas that is involved in scavenging activity, particularly erythrophagocytosis, formation of mature (nonepithelioid granulomas), and heterotypic aggregation with eosinophils.
  • [MeSH-major] Adenocarcinoma / pathology. Granuloma / pathology. Macrophages / immunology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19929174.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD68 antigen, human
  •  go-up   go-down


70. Crist KA, Zhang Z, You M, Gunning WT, Conran PB, Steele VE, Lubet RA: Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture. Carcinogenesis; 2005 May;26(5):951-7
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture.
  • Human ovarian cancer is predominantly of epithelial cell origin (>90% of malignant tumors) and most often presents at an advanced stage with poor prognosis.
  • Most animal models of ovarian carcinoma yield thecal/granulosa cell tumors, rather than adenocarcinomas.
  • Induction of adenocarcinoma in 10-45% of rats following an ovarian implantation of 7,12-dimethylbenz[a]anthracene (DMBA) coated silk suture has been reported.
  • Tumor histology was distributed as well differentiated adenocarcinoma (1/23), poorly differentiated adenocarcinoma (8/23), thecal/granulosa cell tumor (8/23), undifferentiated sarcoma (5/23) and one undifferentiated carcinoma with no adeno character.
  • Adenocarcinomas appeared to originate from the ovarian surface epithelium, with focal papillary extension into cystic space.
  • Vimentin positive epithelial cells when present in adenocarcinomas (4/7), showed perinuclear staining, quite distinct from the uniformly stained stromal cells in thecal/granulosa cell tumors (8/8).
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / pharmacology. Adenocarcinoma / chemically induced. Carcinogens / pharmacology. Ovarian Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695234.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-05103
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


71. Shinji A, Hara E, Mukawa K, Mochizuki T, Ohta H, Yamamura N, Oguchi H, Yazawa K, Kajikawa S, Nakamura T: [A case of peritoneal serous papillary adenocarcinoma]. Gan To Kagaku Ryoho; 2009 Mar;36(3):497-500
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of peritoneal serous papillary adenocarcinoma].
  • We were not able to diagnose by cytological diagnosis.
  • For a definite diagnosis she underwent an open biopsy.
  • Histological findings revealed observable papillary adenocarcinoma with psammoma body, carcinoma cells were positive for Ber-EP4 on immunostaining, and ovaries were normal.
  • Thus, we made a diagnosis of peritoneal serous papillary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295280.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


72. Kawakami T, Nabeshima K, Hamasaki M, Iwasaki A, Shirakusa T, Iwasaki H: Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas. Virchows Arch; 2009 Jan;454(1):61-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cluster invasion: a possible link between micropapillary pattern and lymph node metastasis in pT1 lung adenocarcinomas.
  • Lung adenocarcinomas with micropapillary pattern (MPP) are associated with frequent nodal metastasis.
  • We analyzed 146 cases of pT1 lung adenocarcinomas with reference to the presence of MPP, small cluster invasion (SCI), and lymphatic involvement.
  • SCI was defined as markedly resolved acinar-papillary tumor structures with single or small clusters of carcinoma cells invading stroma within fibrotic foci.
  • Thus, SCI could link MPP to nodal metastasis; carcinoma cells with MPP tend to undergo SCI in scars and invade lymphatics in pT1 lung adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Pulmonary Alveoli / pathology. Respiratory Mucosa / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19002492.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


73. von Rahden BH, Stein HJ, Becker K, Siewert RJ: Esophageal adenocarcinomas in heterotopic gastric mucosa: review and report of a case with complete response to neoadjuvant radiochemotherapy. Dig Surg; 2005;22(1-2):107-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal adenocarcinomas in heterotopic gastric mucosa: review and report of a case with complete response to neoadjuvant radiochemotherapy.
  • Adenocarcinomas are exceedingly rare in the cervical esophagus (26 reported cases), where squamous cell cancer (SCC) is the predominant tumor type.
  • Esophageal heterotopic gastric mucosa (HGM) - a frequent remnant of incomplete replacement of the original columnar epithelium during the embryonic period - is suspected as cellular origin of cervical esophageal adenocarcinomas.
  • As in any rare tumor entity, no standard treatment strategy is available for cervical esophageal adenocarcinomas.
  • We herein report about the case of a 52-year-old man with a locally advanced, irresectable cervical esophageal adenocarcinoma originating in HGM.
  • This is the first case with complete response of a rare cervical esophageal adenocarcinoma to a neoadjuvant protocol.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / therapy. Choristoma / epidemiology. Esophageal Neoplasms / epidemiology. Esophageal Neoplasms / therapy. Gastric Mucosa. Neoadjuvant Therapy
  • [MeSH-minor] Adenocarcinoma, Papillary / epidemiology. Adenocarcinoma, Papillary / surgery. Adenocarcinoma, Papillary / therapy. Chemotherapy, Adjuvant. Esophageal Diseases. Humans. Lymph Node Excision. Male. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849472.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 47
  •  go-up   go-down


74. Furukawa T: Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg; 2007;14(3):233-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas.
  • Intraductal papillary-mucinous neoplasms of the pancreas show characteristic clinicopathological and molecular pathobiological features which are distinct from those of conventional ductal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Papillary / genetics. Biomarkers, Tumor / genetics. Carcinoma, Pancreatic Ductal / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Disease Progression. Dual Specificity Phosphatase 6 / genetics. Dual Specificity Phosphatase 6 / metabolism. Humans. Prognosis. Smad4 Protein / genetics. Smad4 Protein / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520197.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / SMAD4 protein, human; 0 / Smad4 Protein; EC 3.1.3.48 / DUSP6 protein, human; EC 3.1.3.48 / Dual Specificity Phosphatase 6
  • [Number-of-references] 47
  •  go-up   go-down


75. Gulwani H, Jain A: Primary papillary mucinous adenocarcinoma of the ureter mimicking genitourinary tuberculosis. Patholog Res Int; 2010;2010:738407

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary papillary mucinous adenocarcinoma of the ureter mimicking genitourinary tuberculosis.
  • Primary adenocarcinomas of the renal pelvis and ureter are rare and account for less than 1% of all malignancies at this site.
  • We report a case of primary papillary mucinous adenocarcinoma of the ureter that clinically mimicked genitourinary tuberculosis.
  • Early diagnosis is important for the better outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151719.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2990121
  •  go-up   go-down


76. Kim TH, Kim JK, Jang EH, Lee JH, Kim YB: Papillary adenocarcinoma arising in a tubular duplication of the jejunum. Br J Radiol; 2010 Mar;83(987):e61-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma arising in a tubular duplication of the jejunum.
  • In this report, we present the first case of papillary adenocarcinoma arising in a tubular duplication of the jejunum.
  • [MeSH-major] Adenocarcinoma, Papillary / radiography. Jejunal Neoplasms / radiography. Jejunum / abnormalities
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Image Processing, Computer-Assisted. Lymphatic Metastasis. Male. Mesenteric Artery, Superior. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Turk J Pediatr. 2000 Apr-Jun;42(2):118-25 [10936977.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):93-4 [11869024.001]
  • [Cites] J Gastroenterol. 2003;38(8):781-5 [14505134.001]
  • [Cites] J Clin Pathol. 2004 Apr;57(4):428-31 [15047751.001]
  • [Cites] Am J Dis Child. 1971 Dec;122(6):501-6 [5145872.001]
  • [Cites] J Pathol. 1981 Jan;133(1):25-31 [7205440.001]
  • [Cites] Cancer. 1981 Feb 1;47(3):602-9 [7226009.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;415(4):383-5 [2505449.001]
  • [Cites] Radiographics. 1999 Sep-Oct;19(5):1219-36 [10489177.001]
  • [Cites] AJR Am J Roentgenol. 2006 Mar;186(3):895-7 [16498127.001]
  • [Cites] Pathol Int. 2006 May;56(5):272-8 [16669876.001]
  • [Cites] Abdom Imaging. 2008 Sep-Oct;33(5):601-3 [17912582.001]
  • [Cites] Int J Surg Pathol. 2011 Oct;19(5):681-4 [18611942.001]
  • (PMID = 20197430.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3473542
  •  go-up   go-down


77. Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA: Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol; 2010 Jan;133(1):133-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases.
  • Sixteen cases of primary oncocytic adenocarcinomas of the lung are reported.
  • Surgical staging disclosed 14 patients (88%) with stage I disease, 1 (6%) with stage II, and 1 (6%) with stage III.
  • Histologically, all the cases displayed prominent oncocytic features with conventional growth patterns, including acinar, papillary, and bronchioloalveolar.
  • These cases represent an unusual variant of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Oxyphil Cells / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023269.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


78. Zheng HC, Zheng YS, Xia P, Xu XY, Xing YN, Takahashi H, Guan YF, Takano Y: The pathobiological behaviors and prognosis associated with Japanese gastric adenocarcinomas of pure WHO histological subtypes. Histol Histopathol; 2010 04;25(4):445-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathobiological behaviors and prognosis associated with Japanese gastric adenocarcinomas of pure WHO histological subtypes.
  • To clarify the pathobiological behaviors and prognosis of Japanese gastric adenocarcinoma, we analyzed the clinicopathological characteristics of different WHO subtypes of carcinomas.
  • The majority of cases were well-, poorly-, or moderately-differentiated subtype, whereas the minority were papillary or signet ring cell carcinoma (SRC).
  • Survival analysis indicated that the patients with poorly-differentiated or mucinous subtypes had a lower cumulative survival rate than those with papillary, well-, moderately-differentiated, or SRC carcinomas (P<0.05).
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / classification. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Signet Ring Cell / classification. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Fluorescent Antibody Technique, Direct. Gastrectomy. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tissue Array Analysis. World Health Organization


79. Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H: Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol; 2010 Mar;5(3):333-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator.
  • OBJECTIVE: Lung adenocarcinomas 2 cm or less in diameter were studied to develop histologic criteria predicting the outcome.
  • MATERIALS AND METHODS: We reviewed 510 consecutive lung adenocarcinomas 2 cm or less in diameter and assessed three histologic parameters to implement a histologic scoring system: lymphovascular invasion, maximum diameter of the nonbronchioloalveolar carcinoma (BAC) component, and percentage of the solid, cribriform, and/or papillary component in the entire tumor volume (%solid/cribriform/papillary).
  • One point was given to each of lymphovascular invasion-positive, non-BAC >10 mm and %solid/cribriform/papillary > or =30%, and by the sum of these points, a score of 0 to 3 was assigned for each tumor.
  • We also evaluated minimally invasive adenocarcinomas comprising non-BAC < or =5 mm, Sakurai grades 1 and 2.
  • RESULTS: Five-year disease-free survival rates of 287 patients with a histologic score of 0, 69 with a score of 1, 64 with a score of 2, and 90 with a score of 3 were 98.9%, 92.4%, 78.4%, and 54.0%, respectively.
  • The 510 tumors included 129 noninvasive and 127 minimally invasive adenocarcinomas.
  • In remaining 254 patients with overtly invasive adenocarcinomas, 5-year disease-free survival rates in 51 with a histologic score of 0, 49 with a score of 1, 64 with a score of 2, and 90 with a score of 3 were 95.9%, 89.2%, 79.4%, and 54.2%, respectively.
  • CONCLUSION: The histologic scoring system comprising lymphovascular invasion-positive, non-BAC >10 mm and %solid/cribriform/papillary > or =30% is able to predict the outcome of lung adenocarcinomas 2 cm or less in diameter not only in all cases but also in overtly invasive adenocarcinomas.
  • Minimally invasive adenocarcinomas did not recur in this large series.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology. Small Cell Lung Carcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20125041.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, Tanaka A: Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathol Int; 2005 Feb;55(2):63-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas.
  • The expression of claudin-4 was investigated in human pancreas, pancreatic ductal adenocarcinomas, and intraductal papillary-mucinous tumors of the pancreas (IPMT), and compared with that of claudin-1.
  • Of 12 cases of pancreatic ductal adenocarcinoma, 11 (92%) had positive immunostaining for claudin-4, and seven (58%) for claudin-1.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Papillary / metabolism. Carcinoma, Pancreatic Ductal / metabolism. Membrane Proteins / metabolism. Pancreatic Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693851.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


81. Lü K, Dai Q, Xu ZH, Zhang YX, Tan L, Yuan Y, Jiang YX: Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas. Chin Med Sci J; 2010 Sep;25(3):151-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasonographic characteristics of intraductal papillary mucinous neoplasm of the pancreas.
  • OBJECTIVE: To analyze the clinical and ultrasonographic imaging features of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • METHODS: Twelve patients with IPMN underwent surgery between May 2005 and December 2008, including 4 (33.3%) with adenoma and 8 (66.7%) with adenocarcinoma.
  • The mean diameters of the lesions were 1.4 +/- 0.8 cm (range, 0.5-2.0) and 6.3 +/- 6.0 cm (range, 2.0-20.0) in adenomas and adenocarcinomas, respectively.
  • And the mean diameters of the main duct in adenomas and adenocarcinomas were 1.0 +/- 0.8 cm and 1.6 +/- 1.0 cm, respectively.
  • Among the 8 adenocarcinomas, 5 (62.5%) cases were classified as main duct type, and 3 (37.5%) as combined type.
  • In 7 of the 8 adenocarcinomas, mural nodules were detected within the dilated ducts or cysts of the lesions in which color flow signals were detected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21180276.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


82. Ong YK, Chee NW, Hwang PY, Goh J: Endolymphatic sac tumour: a rare cause of recurrent vertigo. Singapore Med J; 2006 Jul;47(7):627-30
MedlinePlus Health Information. consumer health - Dizziness and Vertigo.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endolymphatic sac tumours are rare papillary adenocarcinomas that arise from the endolympatic sac.
  • It can be mistaken both on radiology and histology for other tumours such as paragangliomas, renal or papillary thyroid carcinoma metastases.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Ear Neoplasms / diagnosis. Endolymphatic Sac / pathology. Vertigo / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810439.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


83. Altorjay A, Paal B, Sohar N, Kiss J, Szanto I, Sohar I: Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus. World J Gastroenterol; 2005 Oct 7;11(37):5751-6
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus.
  • AIM: To establish whether there are fundamental differences in the biochemistries of adenocarcinomas of the gastroesophageal junction (GEJ) and the squamous cell carcinomas of the lower third of the esophagus (LTE).
  • Of these, 29 were adenocarcinomas of the GEJ Siewert type I (n = 8), type II (n = 12), type III (n = 9), and 18 presented as squamous cell carcinomas of the LTE.
  • These data were further analyzed to establish the correlation with tumor localization, TNM stage (lymph-node involvement), histological type (papillary, signet-ring cell, tubular), state of differentiation (good, moderate, poor), and survival (<or=24 or >or=24 mo).
  • RESULTS: In adenocarcinomas, the activity of alpha-mannosidase (AMAN), cathepsin B (CB) and dipeptidyl-peptidase I (DPP I) increased significantly as compared to the normal gastric mucosa.
  • There was a statistical correlation of AMAN, CB, and DPP I activity between the level of differentiation of adenocarcinomas of the GEJ and lymph node involvement, because tumors with no lymph node metastases histologically confirmed as well-differentiated, showed a significantly lower activity.
  • CONCLUSION: Adenocarcinomas of the GEJ form a homogenous group from a tumor-biochemical aspect, and differ from the biochemical characteristics of squamous cell carcinomas of the LTE on many points.
  • When adenocarcinomas of the GEJs are examined at the preoperative phase, the ratio of the performed AMAN, CB, and DPP I enzymatic activity of the tissue sample from the tumor and adjacent intact mucosa within 2 cm of the tumor may have a prognostic value even in the preoperative examination period, and may indicate that ranking of these patients into the neo-adjuvant treatment group should be considered.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Squamous Cell. Esophageal Neoplasms. Gastrointestinal Neoplasms. Lysosomes / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270380.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4479671
  •  go-up   go-down


84. Hong SM, Kelly D, Griffith M, Omura N, Li A, Li CP, Hruban RH, Goggins M: Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol; 2008 Dec;21(12):1499-507
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.
  • Ductal adenocarcinoma of the pancreas is the fourth leading cause of cancer death and is usually diagnosed late.
  • Intraductal papillary mucinous neoplasms are an increasingly recognized precursor to invasive ductal adenocarcinoma of the pancreas.
  • Identifying the alterations in DNA methylation that arise during intraductal papillary mucinous neoplasm development may facilitate the development of markers that could be used to differentiate intraductal papillary mucinous neoplasms from non-neoplastic pancreatic cystic lesions.
  • Surgically resected intraductal papillary mucinous neoplasms and adjacent ductal adenocarcinomas were microdissected from 50 patients.
  • Normal pancreas was also obtained from 27 patients with intraductal papillary mucinous neoplasms or pancreatic adenocarcinomas and 10 patients with well-differentiated pancreatic endocrine neoplasms.
  • Methylation-specific PCR was performed on isolated DNA for seven genes (SPARC, SARP2, TSLC1, RELN, TFPI2, CLDN5, UCHL1) known to be commonly aberrantly methylated in pancreatic ductal adenocarcinomas.
  • The mean percentage of genes methylated in invasive ductal adenocarcinomas arising in association with an intraductal papillary mucinous neoplasm (mean+/-s.d., 81+/-17%) was significantly higher than that in noninvasive-intraductal papillary mucinous neoplasms (57+/-26%, P=0.007) or peritumoral normal epithelial cells (22+/-17%, P<0.0001).
  • Carcinomas (intraductal papillary mucinous neoplasms with carcinoma in situ or their associated infiltrating adenocarcinoma) had significantly more methylated genes (71+/-19%) than low-grade (low and moderate dysplasia) intraductal papillary mucinous neoplasms (44+/-26%, P<0.0001).
  • Thus, aberrant DNA methylation increases with histologic grades of intraductal papillary mucinous neoplasm.
  • The detection of aberrant methylation in pancreatic cystic lesions could facilitate the diagnosis of intraductal papillary mucinous neoplasms.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Gastroenterology. 2006 Feb;130(2):548-65 [16472607.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1745-54 [12000726.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):365-72 [12105864.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):293-6 [12432281.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 [12673124.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3735-42 [12839967.001]
  • [Cites] Oncogene. 2003 Aug 7;22(32):5021-30 [12902985.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2634-8 [15059921.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Ann Surg. 2006 May;243(5):673-80; discussion 680-3 [16633003.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 [16682259.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3851-5 [16778113.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):319-25 [17235047.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):987-93; discussion 993-5 [17481526.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6019-25 [17947463.001]
  • [Cites] Virchows Arch. 2007 Nov;451(5):863-9 [17899180.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):243-9 [18027059.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):850-8 [15592528.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):573-83 [15701843.001]
  • [Cites] J Gastroenterol. 2005 Jul;40(7):744-51 [16082592.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • (PMID = 18820670.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / P50 CA062924-140011; United States / NCI NIH HHS / CA / CA062924-149002; United States / NCI NIH HHS / CA / CA062924-150011; United States / NCI NIH HHS / CA / P50 CA062924-149002; United States / NCI NIH HHS / CA / P50 CA062924-159002; United States / NCI NIH HHS / CA / P50 CA062924-150011; United States / NCI NIH HHS / CA / CA062924-159002; United States / NCI NIH HHS / CA / CA062924-140011
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Osteonectin
  • [Other-IDs] NLM/ NIHMS105558; NLM/ PMC2678809
  •  go-up   go-down


85. Yasuda M, Miyazawa M, Fujita M, Kajiwara H, Iida T, Hirasawa T, Muramatsu T, Murakami M, Mikami M, Saitoh K, Shimizu M, Takekoshi S, Osamura RY: Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep; 2008 Jan;19(1):111-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character.
  • The expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) was immunohistochemically analyzed in ovarian adenocarcinomas with the aim of elucidating whether hypoxic status is associated with histological type or structural character.
  • The following ovarian adenocarcinomas were used: serous adenocarcinoma (SEA), 21 cases; mucinous adenocarcinoma (MUA), 19 cases; endometrioid adenocarcinoma (ENA), 16 cases; clear cell adenocarcinoma (CLA), 19 cases.
  • Our results show that GLUT-1 overexpression is to some extent regulated by HIF-1alpha and is also strongly associated with histological features, i.e., papillary or stratified structure accompanied by little or no vascular stroma.
  • In conclusion, hypoxic status differs according to the histological type of ovarian adenocarcinoma and the micro-environmental conditions of each type.
  • [MeSH-major] Adenocarcinoma / pathology. Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Cell Hypoxia / physiology. Excitatory Amino Acid Transporter 2 / biosynthesis. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097583.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Excitatory Amino Acid Transporter 2; 0 / RNA, Messenger; 0 / endothelial PAS domain-containing protein 1
  •  go-up   go-down


86. Jo VY, Mills SE, Cathro HP, Carlson DL, Stelow EB: Low-grade sinonasal adenocarcinomas: the association with and distinction from respiratory epithelial adenomatoid hamartomas and other glandular lesions. Am J Surg Pathol; 2009 Mar;33(3):401-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade sinonasal adenocarcinomas: the association with and distinction from respiratory epithelial adenomatoid hamartomas and other glandular lesions.
  • Sinonasal adenocarcinomas (SNACs) are uncommon malignancies that show a variety of growth patterns.
  • Nine (31%) low-grade SNACs demonstrated a predominantly exophytic and papillary growth pattern, and 18 (72%) had a more tubular growth pattern.
  • This association of low-grade tubular SNACs with REAHs suggests that REAHs may be related to some adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Hamartoma / pathology. Nose Neoplasms / pathology. Paranasal Sinuses / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011560.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Sueda T: Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery; 2006 Sep;140(3):448-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.
  • BACKGROUND: Intraductal papillary-mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) of the pancreas have similar clinicopathologic findings.
  • RESULTS: IPMNs consisted of 32 adenomas, 12 borderline neoplasms, 13 adenocarcinomas in situ, and 13 invasive adenocarcinomas; MCNs included 6 adenomas and 1 invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Ovary / cytology. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgery. 2007 Apr;141(4):545-6 [17383536.001]
  • (PMID = 16934608.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Morikawa H, Tanaka T, Hamaji M, Ueno Y, Hara A: Papillary adenocarcinoma developed in a thymic cyst. Gen Thorac Cardiovasc Surg; 2010 Jun;58(6):295-7
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenocarcinoma developed in a thymic cyst.
  • Microscopic examination revealed that the nodular excrescence of the wall to be limited to papillary adenocarcinoma and the cyst wall to be lined by cuboidal cells.
  • On the basis of this diagnosis, we performed multidrug adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Mediastinal Cyst / pathology. Thymus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549461.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Tanaka M, Fukushima N, Noda N, Shibahara J, Kokudo N, Fukayama M: Intraductal oncocytic papillary neoplasm of the bile duct: clinicopathologic and immunohistochemical characteristics of 6 cases. Hum Pathol; 2009 Nov;40(11):1543-52
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal oncocytic papillary neoplasm of the bile duct: clinicopathologic and immunohistochemical characteristics of 6 cases.
  • Intraductal oncocytic papillary neoplasm is known as a distinct subtype of intraductal papillary mucinous neoplasm of the pancreas.
  • Similar neoplasms of the bile duct are rarely reported, and their disease characteristics are not well established.
  • Grossly, 4 appeared to be cystic neoplasms with papillary projections located in the liver and the other two were papillary neoplasms of the dilated hilar bile duct that ranged from 1.5 to 16 cm in size.
  • All neoplasms showed arborized papillary and/or cribriform formations except one, which showed a villous architecture.
  • All neoplasms were adenocarcinomas accompanied by a microscopic minimally invasive carcinoma.
  • Five patients lived disease-free for 10 to 112 months after resection, and 1 died of tumor recurrence at 26 months postoperatively.
  • The present series of biliary tumors are intraductal papillary neoplasms with oncocytic features and can be clinicopathologically regarded as counterparts of pancreatic intraductal oncocytic papillary neoplasm.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Papillary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540556.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN18 protein, human; 0 / Claudins; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Membrane Proteins; 0 / Mucin 5AC; 0 / Mucin-6
  •  go-up   go-down


90. Carrizo F, Luna MA: Thyroid transcription factor-1 expression in thyroid-like nasopharyngeal papillary adenocarcinoma: report of 2 cases. Ann Diagn Pathol; 2005 Aug;9(4):189-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid transcription factor-1 expression in thyroid-like nasopharyngeal papillary adenocarcinoma: report of 2 cases.
  • We present the cases of 2 pediatric patients with low-grade nasopharyngeal papillary adenocarcinoma with features suggestive of thyroid origin.
  • The patients remain free of disease 2 and 15 years after treatment, with no evidence of lesions in the thyroid or elsewhere.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Nasopharyngeal Neoplasms / metabolism. Nasopharyngeal Neoplasms / pathology. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7. Keratins / biosynthesis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084450.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  •  go-up   go-down


91. Bansal A, Pradeep KE, Gumparthy KP: An unusual case of low-grade tubulopapillary adenocarcinoma of the sinonasal tract. World J Surg Oncol; 2008;6:54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of low-grade tubulopapillary adenocarcinoma of the sinonasal tract.
  • BACKGROUND: Low-grade papillary adenocarcinomas of the sinonasal tract are rare neoplasms.
  • The biopsy revealed low-grade, non-intestinal type sinonasal tubulopapillary adenocarcinoma.
  • However, this raises the possibility of the utility of this antibody to predict a better clinical outcome in the subset of low grade non-intestinal sinonasal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Paranasal Sinus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Aug;443(2):152-8 [12827515.001]
  • [Cites] Histopathology. 2004 Sep;45(3):254-9 [15330803.001]
  • [Cites] Cancer. 1982 Jul 15;50(2):312-22 [7083137.001]
  • [Cites] Histopathology. 2006 Jun;48(7):881-4 [16722945.001]
  • [Cites] Am J Surg Pathol. 1991 Apr;15(4):368-75 [2006716.001]
  • [Cites] Acta Oncol. 1997;36(1):45-50 [9090965.001]
  • [Cites] Arch Otorhinolaryngol. 1985;241(2):183-93 [3977770.001]
  • (PMID = 18492272.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TTF1 protein, human
  • [Other-IDs] NLM/ PMC2426684
  •  go-up   go-down


92. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, Travis WD, Moreira AL: A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol; 2010 Aug;34(8):1155-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors.
  • Currently no objective grading system for pulmonary adenocarcinomas exists.
  • The concordance of the predominant histologic pattern in the primary tumor and the metastases was of 100% for micropapillary, 86% for solid, 42% for acinar, and 23% for papillary types of adenocarcinoma.
  • Grade I, a pattern with low metastatic potential (BAC); Grade II, patterns with intermediate metastatic potential (acinar and papillary); and Grade III, patterns with high metastatic potential (solid and micropapillary).
  • These grades were combined into a number of different scoring systems, whose ability to predict recurrence or death from disease was tested in 366 stage 1 adenocarcinomas.
  • A score based on the 2 most predominant grades was able to stratify patients into low-to-high risk for recurrence or death of disease (P=0.001).
  • The 5-years disease-free survival for patients in the highest score group was of 0.73, compared with 0.84 and 0.92 in the intermediate and lowest score groups.
  • Therefore, this scoring system provides valuable information in discriminating patients with different risk of disease-recurrence in a highly homogeneous population of patients with stage I cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases as Topic. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. New York City. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551825.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Sofuni A, Iijima H, Moriyasu F, Nakayama D, Shimizu M, Nakamura K, Itokawa F, Itoi T: Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol; 2005 May;40(5):518-25
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of pancreatic tumors using ultrasound contrast imaging.
  • BACKGROUND: The development of equipment and contrast agents for ultrasound imaging has contributed to major breakthroughs in the diagnosis of pancreatic tumors.
  • METHODS: We studied 50 cases of histologically proven pancreatic disease; 39 carcinomas, 2 endocrine tumors, 4 intraductal papillary mucinous carcinomas (IPMCs), and 5 cases of tumor-forming pancreatitis (TFP).
  • The histological diagnosis in all cases was made from either biopsy or surgical specimens.
  • Results of comparison between the CE-US findings and the histological diagnosis were as follows.
  • The one papillary adenocarcinoma showed a hypervascular and hyperperfusion pattern; the 32 well or moderately differentiated adenocarcinomas showed a hypovascular and hypoperfusion pattern; and in the poorly differentiated adenocarcinomas, 2 cases of scirrhous type showed a hypovascular and hypoperfusion pattern, and the 4 cases of medullary type showed an isovascular and isoperfusion pattern.
  • CE-US, by the ADI technique, is useful for the diagnosis of pancreatic tumors.
  • [MeSH-major] Adenocarcinoma, Papillary / ultrasonography. Carcinoma, Pancreatic Ductal / ultrasonography. Contrast Media / pharmacology. Pancreatic Neoplasms / ultrasonography. Pancreatitis / ultrasonography
  • [MeSH-minor] Case-Control Studies. Confidence Intervals. Diagnosis, Differential. Female. Humans. Image Enhancement. Male. Neoplasm Staging. Probability. Sensitivity and Specificity. Single-Blind Method

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942718.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


94. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Sueda T: Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg; 2007 Mar;11(3):338-44
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas.
  • The aim of this study was to identify useful preoperative diagnostic findings indicative of malignant or invasive intraductal papillary-mucinous neoplasms (IPMN) of the pancreas to determine an optimal operative procedure for IPMN.
  • Sixty-two IPMNs, which consisted of 29 adenomas, 10 borderline tumors, 11 adenocarcinomas in situ, and invasive adenocarcinomas were reviewed from 1990 to 2003.
  • Preoperative predictive factors of malignant or invasive IPMN were analyzed among 10 factors by univariate and multivariate analysis.
  • Diameter of the main pancreatic duct (> or =6 mm) and cytological examination of the pancreatic juice (the presence of malignant cells) were identified as independent predictive factors of malignant IPMN, and only cytological examination of the pancreatic juice (the presence of malignant cells) was identified as an independent predictor of invasive IPMN by multivariate analysis (P < 0.05).
  • There was no recurrent disease in patients with adenoma and adenocarcinoma in situ, whereas recurrences occurred in 6 of 12 patients with invasive IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458608.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, Fukuda E, Shimamoto F, Sueda T, Hiyama E: Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. J Gastrointest Surg; 2008 Jan;12(1):17-28; discussion 28-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has been increasingly identified as a precursor to infiltrating ductal adenocarcinoma.
  • Samples from pancreatic ductal adenocarcinomas (PDACs, n=15) and chronic pancreatitis patients (n=10) were also examined.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Pancreatic Neoplasms / pathology. Telomerase / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Enzyme Activation. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Telomere / genetics. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17960465.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


96. Melnikov A, Scholtens D, Godwin A, Levenson V: Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn; 2009 Jan;11(1):60-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a previously developed microarray-based technique, we evaluated differences in DNA methylation profiles in a panel of 56 genes using sections of serous papillary adenocarcinomas and uninvolved ovaries (n=30) from women in a high-risk group.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2005;33(10):e93 [15944447.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jun;159(2):114-22 [15899382.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):20-6 [16188302.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):299-308 [16773633.001]
  • [Cites] Cancer Biol Ther. 2006 Oct;5(10):1369-74 [16969071.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):22-6 [17218847.001]
  • [Cites] Recent Results Cancer Res. 2007;174:91-100 [17302189.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):93-101 [18165279.001]
  • [Cites] BJOG. 2000 Feb;107(2):165-9 [10688498.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1121-7 [11238060.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4258-65 [11358853.001]
  • [Cites] Bioinformatics. 2001;17 Suppl 1:S157-64 [11473005.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):61-7 [11773283.001]
  • [Cites] Int J Cancer. 2002 Nov 10;102(2):137-41 [12385008.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6A):3191-6 [12530064.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2000-6 [15041718.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4420-6 [15240532.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Apr;192(4):1214-21; discussion 1221-2 [15846205.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • (PMID = 19074590.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / U01 CA113916; United States / NCI NIH HHS / CA / 5U01 CA113916; United States / NCI NIH HHS / CA / P-50 CA 83638
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2607567
  •  go-up   go-down


97. Striebel JM, Dacic S, Yousem SA: Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma. Am J Surg Pathol; 2008 Mar;32(3):426-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma.
  • A total of 211 cases of primary lung adenocarcinoma were tested for expression of gross cystic disease fluid protein-15 (GCDFP-15) and only 11 cases (5.2%) were positive.
  • The adenocarcinomas were peripheral lesions and had an average size of 2.9 cm (range, 1.1 to 7.0).
  • Histologically, they were usually mixed acinar and papillary adenocarcinomas with abundant extracellular mucin production, with the neoplastic cells having a polygonal shape, round to oval nuclei, diffuse powdery chromatin, and abundant eosinophilic granular cytoplasm.
  • This report details the first 11 cases of pulmonary adenocarcinoma to express GCDFP-15 and their distinctive morphology with frequent mucin production and coexpression of thyroid transcription factor-1 and synaptophysin.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Carrier Proteins / analysis. Glycoproteins / analysis. Lung Neoplasms / chemistry. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / chemistry. Adenocarcinoma, Papillary / pathology. Aged. Female. Histocytochemistry. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mucins / analysis. Nuclear Proteins / analysis. Synaptophysin / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300807.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Mucins; 0 / Nuclear Proteins; 0 / PIP protein, human; 0 / Synaptophysin; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


98. Tanno S, Nakano Y, Sugiyama Y, Nakamura K, Sasajima J, Koizumi K, Yamazaki M, Nishikawa T, Mizukami Y, Yanagawa N, Fujii T, Obara T, Okumura T, Kohgo Y: Incidence of synchronous and metachronous pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm. Pancreatology; 2010;10(2-3):173-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of synchronous and metachronous pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm.
  • BACKGROUND/AIMS: Although branch duct intraductal papillary mucinous neoplasms of the pancreas (BD-IPMN) are being diagnosed with increasing frequency, the incidence of concomitant pancreatic carcinoma (PC) is not well known.
  • The diagnosis of PC was histologically verified in all patients.
  • Five were synchronously detected at the time of BD-IPMN diagnosis, whereas four were metachronously identified during the follow-up period.
  • All PCs represented histologically invasive ductal adenocarcinomas, whereas the BD-IPMN lesion was diagnosed as adenoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Pancreatic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20484955.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


99. Todoroki T, Murata S, Nakagawa Y, Ohkohchi N, Morishita Y: A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. Int Semin Surg Oncol; 2006;3:22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report.
  • BACKGROUND: Tumor spread beyond the peritoneal cavity in cases of papillary serous adenocarcinoma of the unknown primary (CUP) is a rare late event and carries a poor prognosis.
  • Pathological examination revealed the tumors to be metastases of a papillary serous adenocarcinoma with a psammoma body of CUP.
  • CONCLUSION: Aggressive resection surgery followed by effective adjuvant chemotherapy is necessary for surviving long time without relapse of poorly prognostic patients with metastases outside of the abdominal cavity from peritoneal papillary serous adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):16-20 [11301835.001]
  • [Cites] Jpn J Cancer Res. 2001 Jun;92(6):704-9 [11429061.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1003-10 [14997197.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):443-9 [15816609.001]
  • [Cites] DICP. 1990 Mar;24(3):289-95 [2138376.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1091-4 [2400962.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):15-21 [9210704.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • (PMID = 16930493.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574334
  •  go-up   go-down


100. Reid-Nicholson MD, Tong G, Cangiarella JF, Moreira AL: Cytomorphologic features of papillary lesions of the male breast: a study of 11 cases. Cancer; 2006 Aug 25;108(4):222-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic features of papillary lesions of the male breast: a study of 11 cases.
  • Papillary lesions of the male breast are rare and are comprised of a spectrum of lesions ranging from papillary hyperplasia in gynecomastia to invasive papillary carcinoma.
  • The following study describes the cytomorphology of papillary breast lesions in 11 men.
  • METHODS: Archival material (8-year period) from FNA biopsies of papillary lesions of the male breast was reviewed.
  • RESULTS: The smears had variable cellularity but all showed papillary clusters of mammary epithelial cells with and without fibrovascular cores.
  • Single epithelial cells with a high nuclear-to-cytoplasmic ratio and eccentric nuclei were seen in all smears; however, these were more numerous in cases of adenocarcinoma.
  • All adenocarcinomas occurred in older men.
  • CONCLUSIONS: The only cytologic criteria that differentiated benign from malignant papillary lesions were marked cellularity and the presence of abundant 3-dimensional clusters.
  • To the best of the authors' knowledge, the current series is the largest in the English literature to date that examines the cytomorphologic features of papillary breast lesions in men.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms, Male / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Papillary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16721805.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement